Document:

Exhibit 10.13

                 DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT

                                 by and between

                               NOVADEL PHARMA INC.

                                       AND

                            PAR PHARMACEUTICAL, INC.

                                      * * *

                           NITROGLYCERIN LINGUAL SPRAY

                                      * * *

                                  JuLY 28, 2004

<PAGE>

                                TABLE OF CONTENTS

                                                                          Page
                                                                          ----

1.  DEFINITIONS.............................................................1

2.  DEVELOPMENT.............................................................4
    2.1 OBLIGATION TO OBTAIN APPROVAL OF THE PRODUCT........................4
    2.2 BRAND NAME..........................................................4
    2.3 STATUS REPORTING....................................................5

3.  MANUFACTURE AND SUPPLY; COMMERCIALIZATION...............................5
    3.1 COMMERCIALIZATION OVERSIGHT.........................................5
    3.2 SUPPLY AND DISTRIBUTION.............................................6
    3.3 CHANGE IN CIRCUMSTANCES.............................................6
    3.4 FORECASTS...........................................................7
    3.5 CERTAIN PRELIMINARY ASSESSMENTS.....................................7
    3.6 INSUFFICIENCY OF SUPPLY.............................................7

4.  PURCHASING; DELIVERY....................................................8
    4.1 PURCHASE ORDERS.....................................................8
    4.2 PACKAGING...........................................................8
    4.3 DELIVERY............................................................9
    4.4 QUALITY CONTROL AND ASSURANCES AND RELEASE DOCUMENTATION............9
    4.5 ACCEPTANCE AND REJECTION............................................9

5.  PRODUCT PURCHASE PRICE AND PAYMENT TERMS...............................10
    5.1 PURCHASE PRICE.....................................................10
    5.2 ROYALTY PAYMENT....................................................10
    5.3 REPORTS............................................................10

6.  CERTAIN UNDERTAKINGS...................................................11
    6.1 CERTAIN PAYMENTS...................................................11
    6.2 CERTAIN LITIGATION COSTS...........................................11
    6.3 PRODUCT COMPLAINTS AND ADVERSE DRUG EXPERIENCES....................12
    6.4 FACILITY MAINTENANCE; INSPECTION; REPORTS..........................12
    6.5 FILING REQUIREMENTS AND MAINTENANCE................................13
    6.6 INSURANCE..........................................................13

7.  WARRANTIES, INDEMNIFICATION AND LIMITATION OF LIABILITY................13
    7.1 CERTAIN REPRESENTATIONS, WARRANTIES AND COVENANTS OF NOVADEL.......13
    7.2 CERTAIN REPRESENTATIONS, WARRANTIES AND COVENANTS OF PAR...........14
    7.3 REPRESENTATION AND WARRANTIES WITH REGARD TO STATUS................15
    7.4 PRODUCT RECALL.....................................................15
    7.5 NOVADEL'S INDEMNIFICATION OBLIGATIONS..............................16

<PAGE>

                                TABLE OF CONTENTS
                                  (CONTINUED)

    7.6 PAR'S INDEMNIFICATION OBLIGATIONS..................................17
    7.7 SPECIFIC INDEMNITY.................................................17
    7.8 INDEMNIFICATION PROCEDURES.........................................17

8.  AUDIT..................................................................18
    8.1 PAR'S RIGHT TO AUDIT...............................................18
    8.2 NOVADEL'S RIGHT TO AUDIT...........................................18

9.  TERM AND TERMINATION...................................................19
    9.1 TERM...............................................................19
    9.2 TERMINATION FOR BREACH.............................................19
    9.3 TERMINATION FOR BANKRUPTCY.........................................19
    9.4 TERMINATION FOR SUPPLY INTERRUPTION................................19
    9.5 TERMINATION FOR FORCE MAJEURE EVENT................................19
    9.6 TERMINATION FOR EXCESS COSTS.......................................20
    9.7 POST-TERMINATION...................................................20

10. CONFIDENTIALITY........................................................20
    10.1 TREATMENT OF CONFIDENTIAL INFORMATION.............................20
    10.2 LIMITS ON DISCLOSURE..............................................20

11. FORCE MAJEURE..........................................................21
    11.1 EFFECTS OF FORCE MAJEURE..........................................21
    11.2 NOTICE OF FORCE MAJEURE...........................................21
    11.3 ALLOCATION OF CAPACITY............................................21

12. MISCELLANEOUS..........................................................22
    12.1 DISPUTE RESOLUTION................................................22
    12.2 INDEPENDENT CONTRACTORS...........................................22
    12.3 ASSIGNMENT........................................................22
    12.4 GOVERNING LAW; WAIVER OF JURY TRIAL...............................22
    12.5 NO IMPLIED WAIVER.................................................23
    12.6 NOTICE............................................................23
    12.7 AMENDMENTS........................................................24
    12.8 COUNTERPARTS......................................................24
    12.9 ENTIRE AGREEMENT..................................................24
    12.10BENEFIT; BINDING EFFECT...........................................24
    12.11SURVIVAL..........................................................24
    12.12FURTHER ASSURANCES................................................25
    12.13SEVERABILITY......................................................25

                                       ii
<PAGE>

                 DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT

      THIS DEVELOPMENT, MANUFACTURING AND SUPPLY AGREEMENT (this "Agreement"),
dated as of July 28, 2004, by and between NOVADEL PHARMA INC., a Delaware
corporation with an address at 25 Minneakoning Road, Flemington, New Jersey
("NOVADEL"), and PAR PHARMACEUTICAL, INC., a Delaware corporation with an
address at One Ram Ridge Road, Spring Valley, New York ("PAR").

      WHEREAS, Par is engaged in the business of developing, commercializing and
selling pharmaceutical products;

      WHEREAS, NovaDel is engaged in the business of developing, manufacturing
and supplying pharmaceutical products to pharmaceutical companies; and

      WHEREAS, the parties agree to use commercially reasonable efforts to
obtain FDA and any other required governmental approvals to allow for the
manufacture and supply of that certain pharmaceutical product set forth on
Exhibit A hereto (the "Product") by NovaDel or its designee(s) and for the
marketing of the Product by Par or its designee(s), all subject to the terms set
forth herein.

      NOW, THEREFORE, the parties agree as follows:

      1. DEFINITIONS.

      FOR PURPOSES HEREOF, THE FOLLOWING TERMS SHALL HAVE THE MEANINGS SET FORTH
BELOW:

      "ACT" means the Federal Food, Drug, and Cosmetic Act, as amended from time
to time, and the rules and regulations promulgated thereunder.

      "AFFILIATE" means, with respect to any Person, any other Person controlled
by, controlling or under common control with such Person, where control means
more than 50% ownership or voting rights and/or the power to direct management
or policy.

      "APPROVAL NOTICE" has the meaning set forth in Section 2.1 hereof.

      "CGMP" means the current Good Manufacturing Practices regulations of the
FDA (as in effect from time to time) contained in 21 C.F.R. pts. 210 and 211.

      "CLAIM" has the meaning set forth in Section 6.2(a) hereof.

      "COMMERCIALIZATION COMMITTEE" has the meaning set forth in Section 3.1
hereof.

      "CONFIDENTIAL INFORMATION" means any information that in any way shall
relate to a party hereto or an Affiliate thereof, including, without limitation,
its products, business, know-how, methods, trade secrets, business and marketing
strategies, customer lists and technology, that shall be furnished or disclosed
to the other party in connection with this Agreement, and any other information
that would be reasonably recognized as confidential or proprietary information
(including, but not limited to, in the event applicable, the NDA), or that is
designated Confidential Information by the disclosing party; provided, however,
that Confidential Information shall not include any information:

<PAGE>

      (i) that, at the time of disclosure, is generally available to the
public;

      (ii) that, after disclosure in connection herewith, becomes generally
available to the public, except as a result of a breach of this Agreement by the
recipient of such information;

      (iii) that becomes available to the recipient of such information from
a third party that is not legally prohibited from disclosing such Confidential
Information; provided, that such Confidential Information was not acquired,
directly or indirectly, from the disclosing party or its Affiliates; or

      (iv) that the recipient of which can demonstrate was developed by or
for such recipient independently of, and without the use of, the Confidential
Information disclosed by the disclosing party or its Affiliates in connection
herewith.

      "COST OF GOODS" means, (i) with respect to that portion of the
manufacturing, processing, testing, packaging and/or labeling of the Product
performed by NovaDel or its Affiliate(s), NovaDel's or such Affiliate(s)'
actual, direct cost of such activities (including the cost of raw materials),
and (ii) with respect to that portion of the manufacturing, processing, testing,
packaging and/or labeling of the Product performed by a third-party
subcontractor, the price paid by NovaDel to such third-party subcontractor
directly for such activities.

      "EFFECTIVE DATE" means the date of this Agreement.

      "EXCESS COSTS" has the meaning set forth in Section 2.1 hereof.

      "FDA" means the United States Food and Drug Administration or successor
government agency in the United States.

      "FIRST COMMERCIAL SALE" means the first sale of the Product under this
Agreement in an arms' length transaction to an unaffiliated third party.

      "FORCE MAJEURE EVENT" has the meaning set forth in Section 11.1 hereof.

      "INELIGIBLE PERSON" has the meaning set forth in Section 7.3(a) hereof.

      "INITIAL TERM" has the meaning set forth in Section 9.1 hereof.

      "LEGAL EXPENSES" has the meaning set forth in Section 6.2(a) hereof.

      "LOSSES" has the meaning set forth in Section 7.5 hereof.

      "NDA" means the new drug application to be filed by NovaDel with respect
to the Product seeking approval of the Product by the FDA, as the same may be
supplemented and/or amended from time to time.

                                       2
<PAGE>

      "NET SALES" means the gross revenue attributable to the sales of the
Product in the United States or Canada, as applicable, less: (a) returns, price
protections, shelf stock adjustments, rebates (including Medicaid, Medicare and
similar rebates), cash and volume discounts; (b) applicable freight and shipping
costs; (c) applicable shipping insurance costs; and (d) applicable taxes, if
any. If the Product is bundled and sold with other products (a "BUNDLED
PRODUCT"), any additional sales allowance given on the Bundled Products shall be
allocated proportionally among all such Bundled Products based upon a weighted
average of the net selling prices (prior to application of any bundling
allowance) of each such Bundled Product sold.

      "NOVADEL'S FACILITY" means the manufacturing facility for the Product
designated in the NDA.

      "PRODUCT" has the meaning set forth on Exhibit A hereto.

      "PRODUCT APPROVAL" means the non-tentative approval of the NDA by the FDA.

      "PRODUCT MANUFACTURING REQUIREMENTS" has the meaning set forth in Section
3.2(b) hereof.

      "PROPOSED BRAND NAMES" has the meaning set forth in Section 2.2 hereof.

      "PERSON" means an individual, corporation, partnership, company or other
entity.

      "RENEWAL TERM" has the meaning set forth in Section 9.1 hereof.

      "ROYALTY" has the meaning set forth in Section 5.2 hereof.

      "SPECIFICATIONS" means the terms and conditions applicable to the Product
and described in the NDA (or similar filing with a governmental agency in
jurisdictions outside the United States) for the Product, as the same may be
supplemented and/or amended from time to time, and as set forth in the standards
published by USP.

      "TERM" has the meaning set forth in Section 9.1 hereof.

      "TERRITORY" means the United States of America, together with its
territories, possessions and protectorates, and Canada.

      "TRANSFER PRICE" means (i) with respect to that portion of the Product
manufactured, processed, tested, packaged and/or labeled by NovaDel or its
Affiliate(s), the Cost of Goods attributable to such activities plus 10% of such
Cost of Goods, which is deemed to be the overhead component of the Cost of
Goods, and (ii) with respect to that portion of the Product manufactured,
processed, tested, packaged and/or labeled by a third-party subcontractor, the
Cost of Goods attributable to such activities only.

      "USP" means United States Pharmacopeia.

                                       3
<PAGE>

      2. DEVELOPMENT.

      2.1 OBLIGATION TO OBTAIN APPROVAL OF THE PRODUCT. (a) NovaDel shall
use commercially reasonable efforts to obtain Product Approval on the earliest
possible date (given the timing of the regulatory process); provided, that
nothing herein contained shall constitute a guarantee or warranty by NovaDel
that the Product Approval will be obtained; provided, further, that, if the FDA
requires additional development or testing of the Product at an out-of-pocket
cost to NovaDel (for costs incurred after the Effective Date), excluding (i) the
costs of any and all FDA filing fees and (ii) costs associated with the transfer
of manufacturing to a third-party contract manufacturer, that is reasonably
likely to exceed [***] (such excess being referred to herein as the "EXCESS
COSTS"), NovaDel and Par shall negotiate a mutually satisfactory arrangement for
apportionment of the payment of such Excess Costs between the parties, with the
understanding that such Excess Costs shall be recouped by the party(ies) who
pay(s) them from Net Sales of the Product before the payment of any Royalty
payment pursuant to Section 5.2 hereof. Upon its receipt of an approval letter
from the FDA granting the Product Approval, NovaDel shall promptly provide Par
with written notice of the same, including a copy of such approval letter (the
"APPROVAL NOTICE"). [***]

      (b) NovaDel covenants and agrees, on behalf of itself and any applicable
Affiliates, that it shall: (i) devote a commercially reasonable amount of time,
effort, resources and manpower to obtaining the Product Approval; and (ii) not
develop or perform any formulation or developmental or other work on or with
respect to the Product (or any reasonable variant thereof) for its own use or
for the use or benefit of any other Person within the Territory other than as
contemplated by this Agreement.

      (c) Except as otherwise provided in this Section 2.1, the costs and
expenses incurred by NovaDel or its Affiliates in the research, development and
acquisition of the NDA shall be borne solely by NovaDel or its Affiliates. The
costs, expenses and obligations of the post-approval maintenance of the NDA
incurred after (but only after) transfer of the NDA to Par shall be borne solely
by Par.

      (d) Par may, in its sole discretion, seek regulatory approvals to sell the
Product in Canada; provided, that, if Par does not initiate the process to seek
such regulatory approvals within 18 months after NovaDel's delivery of the
Approval Notice to Par, Canada shall cease to be part of the Territory for the
purposes of this Agreement.

      2.2 BRAND NAME.

      Par may, at its option, develop up to five proposed Brand names for
intended use as brand names for the Product in the Territory (the "PROPOSED
BRAND NAMES") and may file trademark application(s) with the U.S. Patent and
Trademark Office directed thereto. NovaDel shall submit the Proposed Brand
Names, in the order of preference designated, in writing, by Par, as the

INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.

                                       4
<PAGE>

possible brand name(s) for the Product in connection with the NDA, and shall, at
Par's written request, amend the NDA with respect thereto. NovaDel shall
promptly apprise Par of any communication from the FDA bearing upon the FDA's
acceptance or rejection of any of the Proposed Brand Names and shall respond
with respect thereto as directed by Par. Par shall own the Proposed Brand Names,
and their use shall inure to the benefit of Par and no right to or license under
the same is granted hereby. Upon the written request of NovaDel, Par may, in its
sole discretion, grant NovaDel a license to use the Proposed Brand Names and the
trademarks related thereto in a region outside the Territory during the Term.

      2.3 STATUS REPORTING.

      NovaDel shall:

      (a) provide Par with copies of all written communications, and written
summaries of all oral communications, from or with the FDA with respect to the
filing and review of the NDA as soon as practicable after, but in any event
within 72 hours (excluding weekends and holidays) of, its receipt thereof, and
NovaDel shall not respond to such written or oral communications without the
prior written consent of Par, which consent shall not be unreasonably withheld
or delayed; provided, that both parties shall use commercially best efforts to
abide by any FDA-imposed deadlines when responding to FDA inquiries and
observations;

      (b) advise Par in writing of any unforeseen material problems or delays
encountered or additional requirements imposed upon NovaDel or its Affiliates,
as the case may be; and

      (c) provide Par with such information as Par may reasonably request in
writing from time to time with respect to the status of the approval of the
Product by the FDA.

      3 MANUFACTURE AND SUPPLY; COMMERCIALIZATION

      3.1 COMMERCIALIZATION OVERSIGHT.

      Oversight of the commercialization of the Product shall be vested in a
commercialization committee (the "COMMERCIALIZATION COMMITTEE"). The
Commercialization Committee shall consist of an equal number of appointees of
each party and shall meet on a regular basis to establish an approximate
timeline for commercial launch of the Product in the United States given the
regulatory process and, following commercial launch, to review marketing and
sales efforts. Notwithstanding the foregoing, the Commercialization Committee
shall be advisory only, and sales and marketing of the Product in the Territory
will be the sole responsibility of Par, which shall have the sole right and
discretion to make all marketing and pricing decisions, including the timing of
the First Commercial Sale. Subject to the foregoing, and provided there are no
pending or threatened Claims, Par shall use commercially reasonable efforts to
launch commercial sale of the Product in the United States within six months
after its receipt of the Approval Notice.

                                       5
<PAGE>

      3.2 SUPPLY AND DISTRIBUTION.

      (a) NovaDel hereby appoints Par as its sole and exclusive distributor for
the Product in the Territory, and Par hereby accepts such appointment and agrees
to act as such sole and exclusive distributor, all upon the terms, conditions
and limitations set forth herein.

      (b) NovaDel shall, directly or through its designee(s), manufacture
and supply to Par, in a timely fashion and in accordance with the terms,
conditions and limitations set forth herein, the Product pursuant to binding
purchase orders submitted by Par pursuant to Section 4.1 hereof. NovaDel, with
the prior written consent of Par, which consent shall not be unreasonably
withheld, shall be allowed to subcontract to a third party the manufacturing
and/or packaging of the Product. NovaDel shall not, and shall not permit its
Affiliates or any other Person to, (i) manufacture for, or supply any of the
Product manufactured by or on behalf of NovaDel to, any Person in the Territory
(other than Par) or outside the Territory to any Person who it has reason to
believe will sell the Product in the Territory, or (ii) sell the Product,
directly or indirectly (other than by Par), in the Territory. NovaDel covenants
that the Product supplied by NovaDel hereunder shall be manufactured (which
shall include, without limitation, all testing, finished dosage form packaging
and labeling) in an FDA-registered facility and in accordance with the following
(collectively, the "PRODUCT MANUFACTURING REQUIREMENTS"): (A) the Specifications
for the Product; (B) applicable cGMP requirements; (C) the most currently
approved version of the NDA; and (D) all other applicable rules, specifications,
regulations and requirements of the FDA relative to the manufacturing of the
Product in the Territory.

      (c) Subject to receipt of the Approval Notice, Par shall use commercially
reasonable efforts to market, distribute and sell the Product in the United
States, either directly and/or through its Affiliates, third-party licensees,
agents and/or designees. Subject to Section 2.1(d) and receipt by Par or its
designees of all regulatory approvals necessary to sell the Product in Canada,
Par shall use commercially reasonable efforts to market, distribute and sell the
Product in Canada, either directly and/or through its Affiliates, third-party
licensees, agents and/or designees. Par shall, subject to Section 3.6 and the
receipt of Product Approval and all necessary Canadian regulatory approvals,
purchase exclusively from NovaDel all of its and its Affiliates' requirements of
the Product for sale in the Territory in accordance with the terms, conditions
and limitations set forth herein.

      3.3 CHANGE IN CIRCUMSTANCES.

      If, at any time, Par reasonably determines that it is not economically
feasible to continue to market and sell the Product in the Territory or in any
portion thereof, Par shall notify NovaDel in writing, and the parties shall
negotiate in good faith for at least 30 days (a) revisions to the Transfer Price
and/or (b) a sublicense of the Product to a third party for marketing in that
portion of the Territory with respect to which Par has made such determination
(which may be the entire Territory). To the extent that the parties shall be
unable to reach an agreement despite the good faith negotiation by the parties,
this Agreement may be terminated by Par upon written notice to NovaDel only with
respect to the rights and obligations to market the Product in such portion of
the Territory (which may be the entire Territory), and Par shall be required to
pay only for Product ordered by or required to be ordered by Par and raw
materials ordered on behalf of Par (which raw materials are not able to be
otherwise reused or resold by NovaDel or its Affiliates or returned to the

                                       6
<PAGE>

supplier of such raw materials upon the exercise of commercially reasonable
efforts) in accordance with Section 3.4 hereof; provided, that upon termination
of this Agreement as it applies to the entire Territory by Par under this
Section 3.3 or by NovaDel under Section 9.2 for Par's material breach, Par shall
grant full rights, title and interest in the NDA and the Proposed Brand Names to
NovaDel.

      3.4 FORECASTS.

      Par shall provide NovaDel with written quarterly forecasts of the
quantities of the Product that it expects to order for each rolling 12-month
period. Such forecasts are estimates and shall represent a commitment for Par to
purchase only the quantity of Product projected for the first month under each
such quarterly forecast and not less than 75% of the amount of Product projected
for the second month and 50% of the amount of Product projected for the third
month under each quarterly forecast. Purchases of Product shall be effected
pursuant to purchase orders submitted by it to NovaDel in accordance with
Section 4.1 hereof. Par shall deliver the first such quarterly forecast no later
than 60 days after the Effective Date, and shall deliver the updated and
extended forecasts every calendar quarter thereafter. NovaDel shall cooperate
with Par in Par's determination of the anticipated First Commercial Sale date
and use commercially reasonable efforts to ship Product to Par at least 60 days
in advance of such date.

      3.5 CERTAIN PRELIMINARY ASSESSMENTS.

      If Par determines: (a) based upon its good faith assessment of its
independent inspection of NovaDel's proposed manufacturing facilities, that
NovaDel has failed to obtain or arrange for the use of manufacturing facilities
adequate to support the commercial launch of the Product, or (b) based upon its
good faith assessment of the patent position of the Product, that there is a
reasonable likelihood that the Product may infringe the intellectual property
rights of a third party; then, in either case, Par may, in its discretion, elect
to terminate this Agreement upon written notice delivered to NovaDel no later
than thirty (30) days after the Effective Date, and NovaDel shall promptly repay
to Par all monies paid by Par to NovaDel pursuant to Section 6.1(a) and 6.1(b)
hereof.

      3.6 INSUFFICIENCY OF SUPPLY.

      Subject to Par's delivery of a forecast and purchase order pursuant to
Sections 3.4 and 4.1, respectively, in the event that NovaDel shall fail or
shall be unable to supply Par's reasonable requirements for the Product
hereunder for a period exceeding 90 cumulative days in any given 365 day period,
then Par may, in its discretion, elect to manufacture the Product, whether
directly or through an Affiliate or third-party manufacturer. If Par elects to
manufacture the Product or cause the Product to be manufactured for Par, (a) Par
shall give NovaDel not less than 30 days notice of Par's intention to do so; (b)
Par shall prepare and submit a supplement to the NDA, and Par or NovaDel, as
appropriate, shall prepare and submit a supplement to any applicable Canadian
regulatory approval, seeking permission for Par, its Affiliate and/or
third-party manufacturer to manufacture such Product; (c) NovaDel shall, upon
the reasonable request of Par, cooperate with, assist and provide Par (or its
Affiliate or third-party manufacturer, as applicable) with all and any
documentation and technology necessary or desirable to allow the manufacture of
the Product in a facility designated by Par and to provide the FDA and/or such
other regulatory agencies with the information necessary to obtain timely

                                       7
<PAGE>

approval to manufacture the Product in the facility chosen by Par; (d) Section
3.4 and Article 4 hereof shall cease to have effect; (e) no Transfer Price shall
be payable to NovaDel hereunder with respect to any Product manufactured by Par,
its Affiliate or third-party manufacturer; (f) the Royalty payable by Par to
NovaDel pursuant to Section 5.2 hereof shall be [***] of Net Sales derived from
sales of the Product in the United States and [***] of Net Sales derived from
sales of the Product in Canada; and (g) the remainder of this Agreement shall
remain in effect. For purposes hereof, Par's "reasonable requirements" shall be
deemed to be any quantity of Product ordered by Par that is up to 120% of the
quantity of Product forecasted by Par for such period pursuant to Section 3.4.

      4 PURCHASING; DELIVERY.

      4.1 PURCHASE ORDERS.

      Subject to the other provisions of this Agreement, Par shall from time to
time, but not before January 1, 2005, place orders for the Product and identify
the requested delivery dates for each such order. The delivery dates specified
in any such orders shall not be less than 60 days from the dates of such orders.
Each order placed pursuant to this Section 4.1 shall constitute a firm
obligation to purchase the ordered quantities of the Product, subject to the
following sentence. Orders may be modified or cancelled by Par upon written
notice to NovaDel; provided, however, that if any modification or cancellation
of an order shall occur less than 45 days prior to the delivery date, Par shall
pay NovaDel within 30 days after invoice therefor any out-of-pocket costs
incurred by NovaDel as a direct result of such modification or cancellation and
which would not otherwise be recovered by NovaDel hereunder. The terms,
conditions and limitations of this Agreement shall be controlling over any
conflicting terms and conditions contained in any purchase order or other
documentation used by Par in ordering the Product or by NovaDel in accepting or
confirming orders, and any term or condition of such purchase order, acceptance
or other document that shall conflict with, or be in addition to, the terms,
conditions and limitations of this Agreement is hereby expressly rejected.

      4.2 PACKAGING.

      NovaDel shall ensure that the Product is packaged with labels, product
inserts and other labeling as reasonably specified and approved by Par and as
required by the FDA. Par may, in its sole discretion, but subject to the
requirements of applicable laws and regulations in the Territory, make changes
to labels, product inserts and other labeling for the Product, which changes
shall be submitted by NovaDel (with the cooperation of Par) prior to NovaDel's
transfer of the NDA to Par, or by Par thereafter, to all applicable governmental
agencies and other third parties responsible for the review and approval of the
Product in the Territory, if required. Par shall reimburse NovaDel for the
actual costs incurred by NovaDel of any labels, product inserts and other
labeling rendered obsolete due to a change precipitated by Par in its sole
discretion;

INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.

                                       8
<PAGE>

provided, that: (a) NovaDel shall provide reasonable documentation of such cost;
(b) the cost of such components shall not be included in the Transfer Price; and
(c) NovaDel shall maintain no more than a reasonable inventory of such labels,
product inserts and other labeling at all times.

      4.3 DELIVERY.

      NovaDel shall use commercially reasonable efforts to ensure that the
Product ordered by Par in accordance with this Agreement is shipped to the
facility designated by Par in accordance with the delivery dates specified in
Par's purchase orders, and NovaDel shall notify Par promptly of any significant
anticipated delay. All Products ordered under this Agreement shall be delivered
FCA (Incoterms 2000) NovaDel's Facility.

      4.4 QUALITY CONTROL AND ASSURANCES AND RELEASE DOCUMENTATION.

      NovaDel shall (or shall cause its designee(s) to) perform all in process
quality control tests and quality assurance reviews on the Product as required
by the Product Manufacturing Requirements and shall certify in writing that each
batch of the Product delivered to Par was manufactured in strict conformity with
the Product Manufacturing Requirements and that the Product contained in such
shipment complies with the provisions of Section 7.1(b) and the other terms of
this Agreement. All deliveries of Product by NovaDel or its designee(s) shall be
accompanied by appropriate documentation required under applicable law to import
the Product into, and for Par to offer the Product for sale in, the Territory,
including any quality assurance or quality control audit results and/or
certifications that the Product Approval for the Product has been audited to
ensure that any Product supplied hereunder has been manufactured in conformity
with cGMP and other applicable regulations in the Territory.

      4.5 ACCEPTANCE AND REJECTION.

      Par shall give written notice to NovaDel of any claims that the Product
manufactured by NovaDel or its designee(s) does not comply with the requirements
of Section 7.1(b) hereof promptly upon its becoming aware of such
non-compliance. In the event that Par shall fail to notify NovaDel of any such
claim within 45 business days of Par's receipt thereof at its facility, such
Products shall be deemed accepted by Par; provided, however, that, other than
with respect to defects or other non-compliance plainly observable from a visual
inspection, any such acceptance or deemed acceptance shall not adversely affect
or otherwise shorten any applicable product warranty period. Any notice by Par
pursuant to this Section 4.5 that any Products do not comply with the terms and
conditions hereof shall be accompanied by a true and correct copy of the results
of any tests conducted by Par thereon, although no such tests are required with
respect to defects or other non-compliance plainly observable from a visual
inspection. The parties shall cooperate in good faith to resolve any disputes
arising therefrom and, in the event that the parties shall be unable to resolve
such dispute within 30 calendar days from the date of Par's notice pursuant to
this Section 4.5, the parties shall submit such dispute to a mutually
satisfactory independent laboratory. The determination by such laboratory shall
be final and binding on the parties and the costs therefor shall be borne by the
non-prevailing party. Par shall not dispose of any Product claimed by it not to
comply with the terms and conditions of this Article 4 until resolution of any
dispute with respect thereto. NovaDel shall (or shall cause its designee(s) to)
promptly replace any Product that does not comply with the terms and conditions

                                       9
<PAGE>

thereof, at NovaDel's sole cost and expense, by delivery thereof to Par. Par
shall pay NovaDel within ten business days for any Products delivered by NovaDel
or such designee(s) and found to be in compliance with the terms and conditions
of this Article 4 after a challenge under this Section 4.5.

      5. PRODUCT PURCHASE PRICE AND PAYMENT TERMS

      5.1 PURCHASE PRICE.

      The purchase price payable by Par for the Product supplied to it by
NovaDel or its designee(s) under this Agreement shall be the Transfer Price. The
purchase price shall be paid within 45 days of Par's receipt of the invoice
therefor; provided, however, that no payment shall be required thereon during
the pendency of any dispute pursuant to Section 4.5.

      5.2 ROYALTY PAYMENT.

      In addition to the amount set forth in Section 5.1, but subject to
reimbursement of Excess Costs pursuant to Section 2.1(a) hereof and the
provisions of Section 6.2(d) hereof, Par shall pay to NovaDel, as a royalty,
[***] of Net Sales derived from sales of the Product in the United States and
[***] of Net Sales derived from sales of the Product in Canada (the "ROYALTY").
Par shall pay the Royalty to NovaDel quarterly, within 45 days after the close
of each calendar quarter; provided, however, that Par may set off such Royalty
payment against any amounts owed to it by NovaDel pursuant to Section 6.2(d)
hereof.

      5.3 REPORTS.

      (a) Within ten days following the end of the calendar quarter in which the
First Commercial Sale occurs, and within ten days following the end of each
subsequent calendar quarter throughout the Term, either party claiming any
amounts payable to it from Net Sales for reimbursement of Excess Costs pursuant
to Section 2.1(a) hereof shall submit to the other a written statement as to the
basis therefor and documentation in reasonable detail justifying such amount.

      (b) Within 45 days following the end of the calendar quarter in which
the First Commercial Sale occurs, and within 45 days following the end of each
subsequent calendar quarter throughout the Term, (i) NovaDel shall submit to Par
a written report in a form reasonably acceptable to both parties setting forth
in reasonable detail NovaDel's calculation of its Cost of Goods and the Transfer
Price with respect to the Product purchased by Par during such calendar quarter
and (ii) Par shall submit to NovaDel a written report in a form reasonably
acceptable to both parties setting forth in reasonable detail Par's calculation
of Net Sales and the Royalty for such calendar quarter.

INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.

                                       10
<PAGE>

      6. CERTAIN UNDERTAKINGS.

      6.1 CERTAIN PAYMENTS.

      In consideration for NovaDel's development of the Product, Par shall make
the following payments to NovaDel upon (and subject to) completion of the
designated events, as follows:

      (a) Concurrently with the parties' execution of this Agreement, Par
shall pay to NovaDel the sum of [***] by wire transfer of immediately available
funds to a bank account of NovaDel previously designated in writing by NovaDel
to Par.

      (b) Within five business days after NovaDel's delivery of written
notice enclosing correspondence from the FDA accepting the NDA for filing, Par
shall pay to NovaDel the sum of [***] by wire transfer of immediately available
funds to a bank account of NovaDel previously designated in writing by NovaDel
to Par. If NovaDel has already received correspondence from the FDA accepting
the NDA for filing at the time of the execution of this Agreement, Par shall,
within five business days after the later of the Effective Date and NovaDel's
delivery of a copy of such correspondence to Par, pay to NovaDel the sum of
[***] by wire transfer of immediately available funds to a bank account of
NovaDel previously designated in writing by NovaDel to Par.

      (c) Within five business days after the later to occur of (i)
NovaDel's delivery of the Approval Notice to Par and (ii) NovaDel's successful
completion of validation of the manufacturing process for the Product, Par shall
pay to NovaDel the sum of [***] by wire transfer of immediately available funds
to a bank account of NovaDel previously designated in writing by NovaDel to Par.

      6.2 CERTAIN LITIGATION COSTS.

      (a) Subject to Section 7 hereof, NovaDel and Par each shall bear [***] of
all legal fees, disbursements and other reasonable expenses incurred to
investigate and defend any claim (including the assertion of any counterclaim
and/or cross-claim) of any Person that the Product infringes any patent or other
proprietary right of such Person enforceable in the Territory (hereafter
referred to as a "CLAIM") (such legal fees, disbursements and other reasonable
expenses, which shall include any judgments, damages, fines, penalties and other
similar assessments in relation to a Claim, being herein referred to
collectively as the "LEGAL Expenses"). NovaDel shall promptly forward to Par
copies of any demands, notices and summonses, cooperate with Par in the
investigation, negotiation, settlement, defense or prosecution of any Claim, and
assist Par, upon Par's request, in the enforcement of any right against any
Person in connection therewith, including by entering into appropriate joint
defense and/or joint privilege agreements.

INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.

                                       11
<PAGE>

      (b) Par shall have sole control over the defense of any Claim, and
NovaDel shall have the right only to be informed of the progress and status
thereof. If NovaDel wishes to be represented with respect to any Claim by
counsel of its own choosing (which shall act in an advisory role only and shall
not participate in the defense of any Claim), such representation shall be at
NovaDel's sole cost and expense. Par shall notify NovaDel (or, at NovaDel's
option, NovaDel's legal counsel) of any material development in any Claim;
provided, that, in the opinion.

      (c) Par may not settle any Claim without the prior written consent of
NovaDel, which consent shall not be unreasonably withheld, delayed or
conditioned; provided, however, that Par may settle or compromise any Claim
without the prior written consent of NovaDel if Par obtains, as a condition of
such settlement or other resolution, a complete and irrevocable release of
NovaDel and its assets.

      (d) NovaDel shall reimburse Par for [***] of the Legal Expenses
incurred by Par pursuant to this Section 6.2 promptly upon receipt from Par of
an invoice providing reasonable documentation thereof.

      6.3 PRODUCT COMPLAINTS AND ADVERSE DRUG EXPERIENCES.

      Par shall be responsible for handling and reporting to the FDA, if
required, all Product complaints and for notifying NovaDel of all such
complaints that relate to manufacturing, packaging or labeling, or where such
notification otherwise is required by FDA regulation, within 30 days of receipt
of any such complaint, and NovaDel shall, upon the reasonable request of Par,
cooperate with and assist Par in its fulfillment of the foregoing obligations.
Par shall notify NovaDel of any report of an adverse drug experience concerning
the Product within five calendar days of receipt of the report and provide
NovaDel with information as required by applicable law and regulations.

      6.4 FACILITY MAINTENANCE; INSPECTION; REPORTS.

      NovaDel shall (and shall cause its third-party manufacturer, if
applicable, to) maintain and operate the manufacturing facility or facilities
designated in the NDA and implement such quality control procedures so as to
meet the requirements of FDA regulations and so as to be able to perform timely
its obligations hereunder. NovaDel shall (and shall cause its third-party
manufacturer, if applicable, to) permit quality assurance representatives of Par
to inspect such manufacturing facility or facilities at all times upon
reasonable notice, during normal business hours and on a confidential basis. Par
shall also be permitted reasonable periodic visits to such manufacturing
facility to discuss manufacturing and supply issues with management of NovaDel
and/or of its third-party manufacturer, if applicable. NovaDel shall (and shall
cause its third-party manufacturer, if applicable, to) promptly provide Par with
a copy of any FDA Form 483 ("Notice of Observations") received at the conclusion
of an inspection relating to the Product and all follow-up correspondence from
the FDA, if any.

INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.

                                       12
<PAGE>

      6.5 FILING REQUIREMENTS AND MAINTENANCE.

      NovaDel (prior to its transfer of the NDA to Par) and Par (after NovaDel's
transfer of the NDA to it) shall promptly comply with all FDA filing and
reporting requirements with respect to the Product and similar filing and
reporting requirements of equivalent governmental agencies in jurisdictions
outside the United States, including, without limitation, all filing and
reporting requirements necessary to keep the NDA current with the FDA. NovaDel
shall be responsible for all stability studies as may be required for ongoing
marketing and sale of the Product and shall, or shall cause its designee(s) to,
conduct such stability studies in compliance with the NDA and FDA requirements.

      6.6 INSURANCE.

      Each of Par and NovaDel shall (and shall cause their respective
Affiliates, as required, to), prior to anticipated receipt of Product Approval
and extending through the remaining term of this Agreement and for a period of
not less than 36 months following the termination of this Agreement, carry or be
subject to coverage under (as a named insured), and name the other party as an
additional named insured under, product liability insurance (including blanket
contractual liability) in an amount of not less than $10,000,000 combined single
limit, which insurance will be written on a "claims-made" policy basis with an
insurance carrier reasonably acceptable to the other party. Each party shall
provide the other party with evidence of coverage contemplated hereby, in the
form of certificates of insurance, as reasonably requested. Such certificates
shall be provided by written notice to the other party 15 days prior to any
material change, cancellation or non-renewal of the policy.

      7. WARRANTIES, INDEMNIFICATION AND LIMITATION OF LIABILITY.

      7.1 CERTAIN REPRESENTATIONS, WARRANTIES AND COVENANTS OF NOVADEL.

      (a) NovaDel hereby represents and warrants to Par that: (i) NovaDel has
the requisite power and authority to enter into this Agreement and perform its
obligations hereunder; (ii) the terms of this Agreement do not conflict with or
breach any agreement to which NovaDel or any Affiliate is a party or by which
NovaDel or any Affiliate is otherwise bound or violate any applicable law; (iii)
NovaDel has developed and tested the Product in a human clinical study; and (iv)
assuming receipt of Product Approval, the proposed marketing and sale of the
Product in the Territory will not, to its knowledge, (A) infringe or violate any
patent or other proprietary right of any other Person (excluding rights in any
trademark utilized at and in accordance with the direction of Par) or (B)
violate any applicable law or regulation.

      (b) NovaDel hereby warrants and covenants to Par that all Product supplied
by it or its designee(s) to Par pursuant to this Agreement shall be
manufactured, tested, packaged, labeled, stored and handled in accordance with
the Product Manufacturing Requirements and that, at the time of the delivery of
such Product to Par, such Product: (i) will meet the Specifications and will not
be adulterated or misbranded within the meaning of the Act or within the meaning
of any applicable Canadian, state or municipal law in which the definitions of
adulteration and misbranding are substantially the same as those contained in
the Act, as such Act and such laws are constituted and effective at the time of

                                       13
<PAGE>

delivery; (ii) will not be an article which may not be introduced into
interstate commerce under the provisions of Sections 404 and 505 of the Act; and
(iii) will have a minimum shelf life of at least 24 months from the date of
manufacture and 21 months from the date of delivery to Par.

      (c) NovaDel hereby represents, warrants and covenants to Par that (i) the
NDA and any other filings made or to be made with the FDA and with equivalent
governmental agencies in jurisdictions outside the United States in connection
with the Product were and shall be, as the case may be, accurate, complete and
truthful when filed and made in good faith upon the best information available
to NovaDel at such time; (ii) the NDA and all other such regulatory filings have
been, or will be, amended, supplemented or otherwise updated in a timely manner
whenever the information contained in any of them is no longer accurate,
complete and truthful, and NovaDel will promptly notify Par in writing of any
such amendment, supplement or other update; and (iii) the Product will be
manufactured, tested, packaged and labeled in accordance with the most current
version of the NDA in effect at the time of manufacturing, testing, packaging
and labeling.

EXCEPT AS OTHERWISE SPECIFICALLY PROVIDED IN THIS AGREEMENT, NOVADEL MAKE NO
REPRESENTATIONS OR WARRANTIES, EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE,
CONCERNING THE DEVELOPMENT OR MANUFACTURE OF THE PRODUCT, INCLUDING THE SUCCESS
OR POTENTIAL SUCCESS THEREOF. EXCEPT AS EXPRESSLY SET FORTH HEREIN, NOVADEL
EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS, WARRANTIES AND AGREEMENTS OF
ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF MERCHANTABILITY AND
FITNESS FOR A PARTICULAR PURPOSE.

PAR UNDERSTANDS THAT THE PRODUCT IS THE SUBJECT OF ONGOING CLINICAL RESEARCH AND
DEVELOPMENT AND THAT NOVADEL CANNOT ASSURE THAT FDA WILL RENDER A POSITIVE
DECISION ON THE SAFETY OR EFFICACY OF THE PRODUCT. NOVADEL MAKES NO
REPRESENTATION OR WARRANTY EXCEPT AS SET FORTH IN THIS ARTICLE 7 CONCERNING ITS
PATENT RIGHTS OR KNOW-HOW.

      7.2 CERTAIN REPRESENTATIONS, WARRANTIES AND COVENANTS OF PAR.

      (a) Par hereby represents and warrants to NovaDel that (i) Par has the
requisite corporate power and authority to enter into this Agreement and perform
it obligations hereunder; and (ii) the terms of this Agreement do not conflict
with or breach any agreement to which Par or any Affiliate is a party or by
which Par or any Affiliate is otherwise bound or violate any applicable law.

      (b) Par hereby covenants to NovaDel that all Product supplied to it by
NovaDel or its designee(s) pursuant to this Agreement shall be stored and
handled by Par in accordance with cGMP.

      (c) Par hereby covenants to NovaDel that it shall not directly promote the
Product for any use other than the uses set forth in the NDA (including any
proposed or approved supplements thereto), except as otherwise permitted by FDA
policy or Par's First Amendment Constitutional rights.

                                       14
<PAGE>

      (d) Par hereby covenants to NovaDel that it will not engage in promotion
and sale of Product in violation of federal and state fraud and abuse laws,
federal and state anti-kick back laws and the Robinson-Patman Act, other than
activities included within the safe harbors established within any agency's
Office of the Inspector General opinions or guidelines, other relevant
guidelines and case law.

THE FOREGOING WARRANTIES IN THIS SECTION 7.2 ARE MADE BY PAR EXPRESSLY IN LIEU
OF ANY AND ALL OTHER EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT BY WAY OF
LIMITATION, THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR
PURPOSE.

      7.3 REPRESENTATION AND WARRANTIES WITH REGARD TO STATUS.

      (a) Subject to the receipt of the Product Approval and similar necessary
approvals in Canada, Par hereby represents and warrants to NovaDel that neither
it nor any of its Affiliates is prohibited by any law, rule or regulation or by
any order, directive or policy from selling the Product or other pharmaceutical
products within the Territory and that neither Par nor any of its Affiliates is
a Person who is listed by a United States federal agency as debarred, suspended,
proposed for debarment or otherwise ineligible for federal programs in the
United States, its territories and protectorates (an "INELIGIBLE PERSON"). Par
hereby covenants to NovaDel that, in the event it subcontracts to a third party
any portion of the commercialization, marketing, supply or sale of the Product,
it shall obtain the foregoing representation from such party to Par and NovaDel
prior to entering into any such subcontracting arrangement.

     (b) Subject to the receipt of the Product Approval and similar necessary
approvals in Canada, NovaDel hereby represents and warrants to Par that neither
it nor any of its Affiliates who have been or are developing the Product or who
is or will be a manufacturer thereof is prohibited by any law, rule or
regulation or by any order, directive or policy from selling the Products and
that neither NovaDel nor any such Affiliate is an Ineligible Person. NovaDel
hereby covenants to Par that, in the event it subcontracts to a third party any
portion of the manufacturing, packaging and/or labeling of the Product, it shall
obtain the foregoing representation from such party to Par and NovaDel prior to
entering into any such subcontracting arrangement.

      7.4 PRODUCT RECALL.

      (a) In the event that either Par or NovaDel determines that a recall of
the Product is necessary for any reason, Par or NovaDel, as applicable, shall so
notify the other in writing. If Par determines to recall the Product, Par shall
give notice of such recall to each customer to which it has sold any applicable
Product, along with the instructions, if any, prepared by Par and/or NovaDel
relating to the recall. The decision to initiate such actions as described above
shall remain solely with Par.

      (b) Except as set forth in Section 7.4(c), in the event of any recall or
seizure of any Product, NovaDel shall, at the written election of Par, either:

                                       15
<PAGE>

      (i) promptly replace the amount of Product recalled or seized; and/or

      (ii) give credit to Par against outstanding receivables due from Par in an
amount equal to the amount paid by Par for the Product (including any portion of
Net Profit payable to NovaDel on such Product) so recalled or seized or
otherwise owing by Par hereunder;

plus  promptly  reimburse  (or,  at the  election  of Par,  credit)  Par for the
aggregate  transportation costs, if any, taxes, freight insurance,  handling and
reasonable and verifiable out-of-pocket costs incurred by Par in respect of such
recalled or seized  Product;  provided,  however,  that the foregoing  shall not
apply if and to the  extent  that  such  recall  or  seizure  arises  out of any
improper act or omission of Par or any third-party subcontractor engaged by Par.
Any costs incurred by NovaDel in complying with its obligations pursuant to this
Section  7.4(b) shall not be,  directly or  indirectly,  passed on to Par in the
calculation of the Transfer Price or otherwise.

      (c) In the event and to the extent that any recall or seizure of any
Product arises out of any act or omission by Par or any third-party
subcontractor engaged by Par, Par shall be responsible (as between Par and
NovaDel) for such recalled or seized product and shall promptly reimburse
NovaDel in cash for any reasonable and verifiable out-of-pocket expenses
incurred by NovaDel in connection therewith.

      (d) For purposes of this Section 7.4, "recall" means (i) any action by
NovaDel, Par or any Affiliate of either to recover title to or possession of any
Product sold or shipped (including, but not limited to, market withdrawal)
and/or (ii) any decision by Par not to sell or ship Product to third parties
that would have been subject to recall if it had been sold or shipped, in each
case taken in the good faith belief that such action was appropriate under the
circumstances. For purposes of this Section 7.4, "seizure" means any action by
any government, authority or agency to detain or destroy any Product.

      (e) NovaDel and Par shall keep the other fully informed in writing of any
notification or other information, whether received directly or indirectly, that
might affect the marketability, safety or effectiveness of any Product, or that
might result in liability issues or otherwise necessitate action on the part of
either party, or that might result in recall or seizure of any Product. NovaDel
(prior to its transfer of the NDA to Par) and Par (after NovaDel's transfer of
the NDA to it) will be responsible for assuring that such recall is closed-out
with the FDA, unless the FDA shall otherwise require.

      7.5 NOVADEL'S INDEMNIFICATION OBLIGATIONS.

      NovaDel shall indemnify and hold Par and its Affiliates and their
respective officers, directors, stockholders, employees and agents
(collectively, the "PAR INDEMNITEES") harmless from and against, and pay or
reimburse, any claim, action, suit, proceeding, loss, liability, damage or
expense (including without limitation reasonable attorneys' fees) ("LOSSES")
arising directly or indirectly as a result of (a) NovaDel's and its third-party
contractors' negligent acts or omissions or willful wrongful acts and (b)
NovaDel's breach of any of its representations, warranties, covenants or other
obligations hereunder; provided, however, that NovaDel shall not be required to
indemnify Par with respect to any Losses to the extent arising from or related
to the negligent acts or omissions or willful wrongful acts of any Par

                                       16
<PAGE>

Indemnitees or Par's breach of its representations, warranties, covenants or
other obligations hereunder, or from information supplied by Par to NovaDel or
contained in regulatory filings or correspondence prepared or delivered by Par.

      7.6 PAR'S INDEMNIFICATION OBLIGATIONS.

      Par shall indemnify and hold NovaDel and its Affiliates and their
respective officers, directors, stockholders, employees and agents
(collectively, the "NOVADEL INDEMNITEES") harmless from and against, and pay or
reimburse, any Losses arising directly or indirectly as a result of (a) Par's
and its third-party contractors' negligent acts or omissions or willful wrongful
acts and (b) Par's breach of any of its representations, warranties, covenants
or other obligations hereunder; provided, however, that Par shall not be
required to indemnify NovaDel with respect to any Losses to the extent arising
from or related to the negligent acts or omissions or willful wrongful acts of
any NovaDel Indemnitees or NovaDel's breach of its representations, warranties,
covenants or other obligations hereunder, or from information supplied by
NovaDel to Par or contained in regulatory filings or correspondence prepared or
delivered by NovaDel.

      7.7 SPECIFIC INDEMNITY.

      In the event that (a) either party or both parties sustains, suffers or
incurs any Losses arising from or relating to any third-party claim to the
extent arising from the use or design of the Product, including product
liability and strict liability claims in respect thereof, or (b) a final,
non-appealable determination shall have been made by a court of competent
jurisdiction that, in respect of such third-party claim, neither party is
negligent or otherwise at fault; then, as applicable, Par shall indemnify
NovaDel from and against [***] ([***]) percent of the Losses sustained by
NovaDel, and NovaDel shall indemnify Par from and against [***] ([***]) percent
of the Losses sustained by Par.

      7.8 INDEMNIFICATION PROCEDURES.

      A party (the "indemnitee") that intends to claim indemnification under
this Article 7 shall notify the other party (the "indemnitor") promptly in
writing of any action, claim or liability in respect of which the indemnitee
believes it is entitled to claim indemnification; provided, that the failure to
give timely notice to the indemnitor shall not release the indemnitor from any
liability to the indemnitee except to the extent the indemnitor is materially
prejudiced thereby. The indemnitor shall have the right, by written notice to
the indemnitee, to assume the defense of any such action or claim, within the
15-day period after the indemnitor's receipt of written notice of any action or
claim, with counsel of the indemnitor's choice and at the sole cost of the
indemnitor. If the indemnitor so assumes such defense, the indemnitee may
participate therein through counsel of its choice, but at the sole cost of the
indemnitee. The party not assuming the defense of any such claim shall render
all reasonable assistance to the party assuming such defense, and all reasonable
out-of-pocket costs of such assistance shall be for the account of the
indemnitor. No such claim shall be settled other than by the party defending the

INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.

                                       17
<PAGE>

same, and then only with the prior written consent of the other party, which
consent shall not be unreasonably withheld; provided, however, that the
indemnitee shall have (a) no obligation to consent to any settlement of any such
action or claim that (i) imposes on the indemnitee any monetary or other
liability or obligation that cannot be assumed and performed in full by the
indemnitor or (ii) adversely affects the indemnitee's rights hereunder or
damages its reputation or business, and (b) no right to withhold its consent to
any settlement of any such action or claim if the settlement involves only the
payment of money by the indemnitor or its insurer and the indemnitor or its
insurer agrees in writing to make such payment.

IN NO EVENT WILL EITHER PARTY BE LIABLE FOR ANY SPECIAL, INCIDENTAL, INDIRECT OR
CONSEQUENTIAL DAMAGES, INCLUDING ANY LOSS OF INCOME, LOSS OF PROFITS, COSTS OF
SUBSTITUTION, COSTS OF COVER OR INCREASED CAPITAL COSTS, REGARDLESS OF THE FORM
OR NATURE OF ACTION, WHETHER IN CONTRACT, BREACH OF WARRANTY, STRICT LIABILITY,
EQUITY, INDEMNITY, NEGLIGENCE, INTENDED CONDUCT, TORT OR OTHERWISE, EVEN IF SUCH
DAMAGES WERE FORESEEABLE OR IF THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF
SUCH DAMAGES.

      8. AUDIT.

      8.1 PAR'S RIGHT TO AUDIT.

      NovaDel shall maintain true and complete books of account containing an
accurate record of all data necessary for proper assessment of the Transfer
Price (including the Cost of Goods) provided in Section 5.1 hereof. Par shall
have the right, through an independent certified public accountant, to examine
NovaDel's books of account related to such matters at any time, on reasonable
prior notice (but not more than twice in any calendar year), within two years
after the end of the calendar year in which the sale was invoiced by NovaDel for
the purpose of verifying the accuracy of such matters. The parties agree that
information furnished to Par as a result of any such examination shall be
limited to a written statement by such certified public accountant to the effect
that they have reviewed the books of account of NovaDel and either (i) NovaDel's
calculations are correct or (ii) setting forth any required adjustments thereto.
If any such audit shows any overpayment by Par, a correcting refund shall be
made within 30 days after receipt of the written statement described above. The
expenses of such audit shall be borne by Par; provided, however, if such audit
shows an overpayment by Par exceeding $10,000, NovaDel shall bear all costs of
the audit.

      8.2 NOVADEL'S RIGHT TO AUDIT.

      Par shall maintain true and complete books of account containing an
accurate record of all data necessary for proper assessment of the Royalty
payment (including Net Sales) provided in Section 5.2 hereof. NovaDel shall have
the right, through an independent certified public accountant, to examine Par's
books of account related to such payment at any time, on reasonable prior notice
(but not more than twice in any calendar year), within two years after the end
of the calendar year in which the Products that are the subject of such payment
were delivered for sale in the Territory for the purpose of verifying the
accuracy of such payment. The parties agree that information furnished to
NovaDel as a result of any such examination shall be limited to a written

                                       18
<PAGE>

statement by such certified public accountant to the effect that they have
reviewed the books of account of Par and either (i) Par's calculations are
correct or (ii) setting forth any required adjustments thereto. If any such
audit shows any underpayment by Par, a correcting payment shall be made within
30 days after receipt of the written statement described above. The expenses of
such audit shall be borne by NovaDel; provided, however, if such audit shows an
underpayment by Par exceeding $10,000, Par shall bear all costs of the audit.

      9. TERM AND TERMINATION.

      9.1 TERM.

      This Agreement shall commence on the Effective Date and continue, unless
otherwise earlier terminated in accordance herewith, for a period that shall
extend ten years from the date of the First Commercial Sale of the Product (the
"INITIAL TERM"); provided, however, that this Agreement may be terminated, at
the election of Par upon written notice thereof to NovaDel, if there shall be no
First Commercial Sale on or before January 1, 2007. Thereafter, this Agreement
shall be automatically renewed for successive two-year periods (each, a "RENEWAL
TERM" and, together with the Initial Term, the "TERM"), unless a party shall
otherwise notify the other in writing at least 12 months prior to the expiration
of the Initial Term or any Renewal Term.

      9.2 TERMINATION FOR BREACH.

      If either party commits a material breach or default in the performance or
observance of any of its material obligations under this Agreement and such
breach or default is not cured within 30 days after receipt by such party of the
written notice from the non-breaching party specifying the breach or default,
then the non-breaching or non-defaulting party shall have the right to terminate
this Agreement with immediate effect by giving written notice to the breaching
or defaulting party.

      9.3 TERMINATION FOR BANKRUPTCY.

      This Agreement shall automatically terminate upon the initiation of any
proceeding in bankruptcy, reorganization or arrangement for the appointment of a
receiver or trustee to take possession of the assets of a party hereto or
similar proceeding under the law for release of creditors by or against a party
hereto or if a party hereto shall make a general assignment for the benefit of
its creditors.

      9.4 TERMINATION FOR SUPPLY INTERRUPTION.

      This Agreement may be terminated by Par, on 30 days' written notice, if
NovaDel shall fail or be unable to supply all Par's requirements for the Product
for a period exceeding 90 cumulative days in any given 365-day period.

      9.5 TERMINATION FOR FORCE MAJEURE EVENT.

      If, as a result of a Force Majeure Event, a party does not perform its
obligations hereunder for any cumulative period of 90 days within any 365-day
period, the other party shall have the right to terminate this Agreement in its

                                       19
<PAGE>

entirety upon providing written notice to the non-performing party, such
termination to be effective within 30 days of such notice.

      9.6 TERMINATION FOR EXCESS COSTS.

      Either party may terminate this Agreement upon advance written notice to
the other party if, within 30 days of identifying the likelihood of Excess Costs
pursuant to Section 2.1 hereof, the parties fail to reach a mutually
satisfactory arrangement with respect to the payment of Excess Costs.

      9.7 POST-TERMINATION.

      If this Agreement is terminated pursuant to Section 9.6 hereof, NovaDel
shall promptly repay to Par any and all amounts paid by Par to NovaDel pursuant
to Section 6.1 hereof. Termination or expiration of this Agreement shall not
affect any payment or other obligations or liabilities that have accrued prior
to the date of such termination or expiration and the parties shall retain all
rights and remedies in response to any breach(es) thereof.

      10. CONFIDENTIALITY.

      10.1 TREATMENT OF CONFIDENTIAL INFORMATION.

      Except as required by applicable laws and regulations (including rules or
regulations of any exchange upon which a party's capital stock may be traded) or
as otherwise provided in this Article 10, during the Initial Term and any
Renewal Term, and thereafter, each party shall hold in confidence, and may not
use for purposes other than those contemplated by this Agreement or disclose to
a third party (except as specifically set forth herein or with the express prior
written consent of the other party) any and all Confidential Information.

      10.2 LIMITS ON DISCLOSURE.

      (a) Without limiting the generality of the foregoing, each party may
disclose Confidential Information to those of its employees, officers,
directors, representatives, contractors, consultants, advisors and agents who
need to receive the Confidential Information in order to further the activities
contemplated in this Agreement; provided, that each such person or entity must
either be made aware of this Article 10 and agree to be bound by it or otherwise
be bound by a duty of confidentiality to such party. Each party shall take
reasonable precautions to safeguard the Confidential Information, including
obtaining appropriate commitments and enforceable confidentiality agreements.
Each party understands and agrees that the wrongful disclosure of Confidential
Information may result in serious and irreparable damage to the other party,
that the remedy at law or any breach of this covenant may be inadequate, and
that the party seeking redress hereunder shall be entitled to injunctive relief,
without prejudice to any other rights and remedies to which such party may be
entitled. Each party shall be liable for the disclosure of confidential
information in violation of this Agreement by its employees, officers,
directors, representatives, contractors, consultants, advisors and agents.

      (b) It is acknowledged that Confidential Information may be obtained by a
party from the other party not only in writing or other tangible form (including
electronic), but also through discussions between each party's respective
representatives, demonstrations, observations and other intangible methods.

                                       20
<PAGE>

      (c) The above notwithstanding, each party shall have the right with the
exercise of reasonable discretion, and insofar as practical under written
confidentiality agreements having provisions no less stringent than those
contained herein, to make disclosures of such portions of Confidential
Information to third party consultants, attorneys, contractors, advisors,
Affiliates and governmental agencies where, in the recipient's judgment, such
disclosure is beneficial to the development, approval or marketing of the
Product pursuant to this Agreement.

      (d) Except as otherwise set forth in this Agreement, upon termination or
expiration of this Agreement and at the written request of the disclosing party,
the receiving party shall return all Confidential Information of the disclosing
party (including all copies, excerpts and summaries thereof contained on any
media) or destroy such Confidential Information at the option of the disclosing
party; provided, that the receiving party may retain one copy of all
Confidential Information of the disclosing party for its legal records.

      11. FORCE MAJEURE.

      11.1 EFFECTS OF FORCE MAJEURE.

      No party hereto shall be held liable or responsible for failure or delay
in fulfilling or performing any of its obligations under this Agreement (other
than the payment of money) if such failure or delay is caused by, without
limitation, acts of God, acts of the public enemy, fire, explosion, flood,
drought, war, terrorists, riot, sabotage, embargo, strikes or other labor
disputes, intervention of governmental agency, or by any other event or
circumstance of like or different character to the foregoing beyond the
reasonable control and without the fault or negligence of the affected party (a
"FORCE MAJEURE EVENT"). Such excuse shall continue as long as the Force Majeure
Event continues. Upon cessation of such Force Majeure Event, subject to Section
9.5 hereof, such party shall promptly resume performance hereunder.

      11.2 NOTICE OF FORCE MAJEURE.

      Each party agrees to give the other party prompt written notice of the
occurrence of any Force Majeure Event, the nature thereof and the extent to
which the affected party will be unable to perform its obligations hereunder.
Each party further agrees to use reasonable efforts to correct or otherwise
address the Force Majeure Event as soon as practicable and to give the other
party prompt written notice when it is again fully able to perform such
obligations.

      11.3 ALLOCATION OF CAPACITY.

      If NovaDel at any time is unable to fully supply the purchase orders of
Par for the Product in accordance with this Agreement, NovaDel shall use
reasonable best efforts to allocate its available resources and production
capacity to the manufacture of the Product to fill orders placed by Par pursuant
hereto to the fullest extent possible.

                                       21
<PAGE>

      12. MISCELLANEOUS.

      12.1 DISPUTE RESOLUTION.

      The parties recognize that a bona fide dispute as to certain matters may,
from time to time, arise during the term of this Agreement which relates to a
party's rights and/or obligations hereunder. In the event of the occurrence of
such a dispute, either party may, by written notice to the other party, have
such dispute referred to their respective officers, designated below, or their
successors, for attempted resolution by good faith negotiation within 30 days
after such notice is received. Such designated officers are as follows:

      For NovaDel: Gary Shangold, President and Chief Executive Officer

      For Par: Scott Tarriff, President and Chief Executive Officer

In the event the designated officers are not able to resolve the dispute within
such 30-day period, or such other period of time as the parties may mutually
agree to in writing, each party shall have the right to pursue any and all
remedies available at law or in equity, subject to Section 4.5 hereof.

      12.2 INDEPENDENT CONTRACTORS.

      The relationship between NovaDel, on the one hand, and, Par on the other
hand, is that of independent contractors and nothing herein shall be deemed to
constitute the relationship of partners, joint venturers nor of principal and
agent between NovaDel on the one hand and Par on the other hand. Neither party
shall have any express or implied right or authority to assume or create any
obligations on behalf of or in the name of the other party or to bind the other
party to any contract, agreement or undertaking with any third party.

      12.3 ASSIGNMENT.

      This Agreement may be assigned and delegated by either party in connection
with any sale, merger or other business combination involving all or
substantially all of the parties' assets or capital stock. Except as set forth
in the preceding sentence, neither this Agreement nor any other rights or
obligations hereunder shall be assigned or delegated by either party without the
prior written consent of the other party, which consent shall not be
unreasonably withheld, conditioned or delayed.

      12.4 GOVERNING LAW; WAIVER OF JURY TRIAL.

      This contract shall be governed by, and construed in accordance with, the
laws of the State of New York. The parties hereby consent to the exclusive
jurisdiction of Federal and New York State courts located in Manhattan, New York
and hereby waive any objection to venue or forum laid therein. The parties
hereby agree that service of process by certified mail, return receipt
requested, shall constitute personal service for all purposes hereof. EACH PARTY
HEREBY WAIVES ITS RIGHT TO A TRIAL BY JURY OF ANY CLAIM OR CAUSE OF ACTION BASED
UPON, ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY, IN ANY ACTION, PROCEEDING OR OTHER LITIGATION OF ANY TYPE
BROUGHT BY ANY PARTY AGAINST THE OTHER, WHETHER WITH RESPECT TO CONTRACT CLAIMS,

                                       22
<PAGE>

TORT CLAIMS OR OTHERWISE. THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS,
RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT.

      12.5 NO IMPLIED WAIVER.

      No failure or delay on the part of the parties hereto to exercise any
right, power or privilege hereunder or under any instrument executed pursuant
hereto shall, in itself, operate as a waiver; nor shall any single or partial
exercise of any right, power or privilege preclude any other or further exercise
thereof or the exercise of any other right, power or privilege.

      12.6 NOTICE.

      All notices required to be given hereunder shall be in writing and shall
be given by personal delivery, via facsimile transmission followed by mailing,
by a nationally recognized overnight carrier or by registered or certified mail,
postage prepaid with return receipt requested. Notices shall be addressed to the
parties as follows:

      If to NovaDel:    NovaDel Pharma, Inc.
                        25 Minneakoning Road
                        Flemington, NJ 08822
                        Attn: Gary Shangold, President and Chief Executive
                              Officer
                              Barry Cohen, Vice President of Business and New
                              Product Development
                        Facsimile No.: (908) 806-7624

      With a copy       Dickstein Shapiro Morin & Oshinsky, LLP
      (which shall      1177 Avenue of the Americas
      not constitute    47th Floor
      notice) to:       New York, NY 10036
                        Attn.:   Ira L. Kotel, Esq.
                        Facsimile No.:  (212) 997-9880

      If to Par:        Par Pharmaceutical, Inc.
                        One Ram Ridge Road
                        Spring Valley, NY  10977
                        Attn: Scott Tarriff, President and Chief Executive
                              Officer
                              Michael Graves, Vice President of Marketing and
                              Business Development
                        Facsimile No.:  (201) 391-7693

      With a copy       Kirkpatrick & Lockhart LLP
      (which shall      599 Lexington Avenue
      not constitute    New York, NY 10022
      notice) to:       Attn: Stephen R. Connoni, Esq.
                              Barry J. Gilman, Esq.
                        Facsimile No.:  (212) 536-3901

                                       23
<PAGE>

Notices delivered personally shall be deemed communicated as of actual receipt;
notices sent via facsimile transmission shall be deemed communicated as of
receipt by the sender of written confirmation of transmission thereof; notices
sent via overnight courier shall be deemed received as of one business day
following sending; and notices mailed shall be deemed communicated as of three
business days after proper mailing. A party may change his or its address by
written notice in accordance with this Section 12.6.

      12.7 AMENDMENTS.

      Any amendment or modification of this Agreement shall be valid only if
made in writing and signed by the parties hereto.

      12.8 COUNTERPARTS.

      This Agreement may be executed in counterparts, each of which shall be
deemed an original and all of which shall constitute a single document.

      12.9 ENTIRE AGREEMENT.

      This Agreement constitutes the entire understanding between the parties
with respect to the subject matter hereof and supersedes all prior contracts,
agreements and understandings related to the same subject matter between the
parties. The parties intend this Agreement to be a complete statement of the
terms of their understanding.

      12.10 BENEFIT; BINDING EFFECT.

      This Agreement shall be binding upon and shall inure to the benefit of the
parties hereto and their respective successors and permitted assigns.

      12.11 SURVIVAL.

      Notwithstanding anything to the contrary contained in this Agreement, the
provisions of Sections 6.6 and 9.7 and Articles 1, 7, 8, 10 and 12 shall
survive, in accordance with their respective terms, any termination of this
Agreement; provided, that, in the case of termination pursuant to Section 3.5,
the provisions of only Articles 1 and 10 shall survive such termination.

                                       24
<PAGE>

      12.12 FURTHER ASSURANCES.

      The parties hereto agree that they shall take all appropriate actions,
including the execution or filing of any documents or instruments, that may be
reasonably necessary or advisable to carry out the intent and accomplish the
purposes of any of the provisions hereof.

      12.13 SEVERABILITY.

      In the event that any provision of this Agreement shall be held invalid or
unenforceable for any reason by a court of competent jurisdiction, such
provision or part thereof shall be considered separate from the remaining
provisions of this Agreement, which shall remain in full force and effect. Such
invalid or unenforceable provision shall be deemed revised to effect, to the
fullest extent permitted by applicable law, the intent of the parties as set
forth therein.

                            [SIGNATURE PAGE FOLLOWS]

                                       25
<PAGE>

      IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed as of the date first above written by their duly authorized
representatives.

                                        NOVADEL PHARMA, INC.

                                        By: /s/ Barry Cohen
                                        ---------------------------------------
                                          Name:  Barry Cohen
                                          Title: Vice President of Business and
                                                 New Product Development

                                        PAR PHARMACEUTICAL, INC.

                                        By: /s/ Michael Graves
                                        ---------------------------------------
                                          Name:  Michael Graves
                                          Title: Vice President of Marketing
                                                 and Business Development

                                       26
<PAGE>

                                    EXHIBIT A
                                    ---------

      |_| Nitroglycerin lingual spray

                                       27Exhibit 10.14

                               SECOND AMENDMENT TO
                               -------------------
                        LICENSE AND DEVELOPMENT AGREEMENT
                        ---------------------------------

      THIS SECOND AMENDMENT TO LICENSE AND DEVELOPMENT AGREEMENT (this
"Agreement"), effective as of June 22, 2004 (the "Effective Date"), is entered
into by and between NOVADEL PHARMA INC., a Delaware corporation ("NOVADEL"), and
THE VETERINARY COMPANY, INC., a Delaware corporation (the "LICENSEE"). NovaDel
and Licensee each may be referred to herein individually as a "Party," or
collectively as the "Parties."

      WHEREAS, NovaDel has certain proprietary rights and intellectual property
(including pursuant to certain patents) with respect to buccal sprays for the
metered delivery of pharmaceutical products (the "Technology"); and

      WHEREAS, Licensee desires to obtain from NovaDel, and NovaDel desires to
grant to Licensee, a license to develop and commercialize certain pharmaceutical
products that will be administered to non-human animals using the Technology on
the terms and conditions set forth herein; and

      WHEREAS, Licensee and NovaDel entered into a License and Development
Agreement as of October 23, 2003 outlining terms of the foregoing (the "Original
Agreement);

      WHEREAS, the Original Agreement was amended as of October 24, 2003 (the
"First Amendment");

      WHEREAS, the Licensee and NovaDel wish to amend the Original Agreement, as
amended by the First Amendment, with this Agreement, and the parties hereby
intend that the Original Agreement and the First Amendment shall be, as of the
date hereof, null and void and that this Agreement shall supercede both the
Original Agreement and the First Amendment in their entirety as of the date
hereof;

      NOW, THEREFORE, in consideration of the foregoing premises, the mutual
promises and covenants of the Parties contained herein, and other good and
valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties hereto, intending to be legally bound, do hereby agree
as follows:

                                    ARTICLE 1
                                   DEFINITIONS

      For the purposes of this Agreement, the following words and phrases shall
have the following meanings, unless otherwise specifically provided herein:

     1.1 "AFFILIATE" shall mean, with respect to any Entity, any other Entity
that directly or indirectly through one or more intermediaries, controls, is
controlled by or is under common control with such Entity. For purposes of this
Article 1.1 only, "control" and, with correlative meanings, the terms
"controlled by" and "under common control with" shall mean (a) the possession,
directly or indirectly, of the power to direct the management or policies of an

<PAGE>

Entity, whether through the ownership of voting securities, by contract or
otherwise, or (b) the ownership, directly or indirectly, of at least fifty
percent (50%) of the voting securities or other ownership interest of an Entity.

     1.2 "APPLICABLE LAW" shall mean the applicable laws, rules, regulations,
guidelines and requirements of the Regulatory Authorities in the Territory.

     1.3 "COMMERCIALLY REASONABLE EFFORTS" shall mean, with respect to the
development or commercialization of a Licensed Product, efforts and resources
commonly used in the research-based pharmaceutical industry for a product of
similar commercial potential at a similar stage in its lifecycle, taking into
consideration its safety and efficacy, its cost to develop, the competitiveness
of alternative products, its proprietary position, the likelihood of regulatory
approval, its profitability, and all other relevant factors. Commercially
Reasonable Efforts shall be determined on a market-by-market basis for each
Licensed Product without regard to the particular circumstances of a Party,
including any other product opportunities of such Party.

     1.4 "CONFIDENTIAL INFORMATION" shall have the meaning set forth in Article
16.

     1.5 "CONTROL" shall mean, with respect to any item of Information and
Inventions, Patent or other intellectual property right, possession of the
ability, whether directly or indirectly, and whether by ownership, license or
otherwise, to assign, or grant a license, sublicense or other right to or under,
such item, Patent or right as provided for herein without violating the terms of
any agreement or other arrangement with any Third Party.

     1.6 "DESIGNATED COMPOUND" shall mean a separate chemical active ingredient
(collectively, the "Designated Compounds" which are each of the First Designated
Compound, Second Designated Compound, Third Designated Compound, Fourth
Designated Compound and Additional Designated Compounds listed on Exhibit 3 when
such compound(s) are added to Exhibit 3. For clarity, it is acknowledged that a
Designated Compound is not a new formulation, salt or ester of a previously
identified Designated Compound. The "First Designated Compound" shall mean the
compound designated as the "First Designated Compound" on Exhibit 3 when and if
such compound is added to Exhibit 3 in accordance with Article 3. The "Second
Designated Compound" shall mean the compound containing a different active
ingredient than the First Designated Compound designated as the "Second
Designated Compound" on Exhibit 3 when and if such compound is added to Exhibit
3 in accordance with Article 3. The "Third Designated Compound" shall mean the
compound containing a different active ingredient than either the First
Designated Compound or the Second Designated Compound designated as the "Third
Designated Compound " on Exhibit 3 when and if such compound is added to Exhibit
3 in accordance with Article 3. The "Fourth Designated Compound" shall mean the
compound containing a different active ingredient than either the First
Designated Compound, the Second Designated Compound or the Third Designated
Compound designated as the "Fourth Designated Compound " on Exhibit 3 when and
if such compound is added to Exhibit 3 in accordance with Article 3. The
"Additional Designated Compound" shall refer to each Designated Compound Exhibit
3 other than the First Designated Compound, Second Designated Compound, Third
Designated Compound, or Fourth Designated Compound.

     1.7 "CANDIDATE COMMITTEE" shall have the meaning set forth in Article
3.2.1.

                                       2
<PAGE>

     1.8 "EFFECTIVE DATE" shall have the meaning set forth in the preamble.

     1.9 "ENTITY" shall mean any individual, sole proprietorship, corporation,
limited liability company, association, joint venture, partnership, limited
partnership, limited liability partnership, trust, university, business,
government or political subdivision thereof, including an agency, or any other
organization that possesses independent legal standing.

     1.10 "EXPLOIT" shall mean to make, have made, import, use, sell, or offer
for sale, including to research, develop, register, modify, improve,
manufacture, have manufactured, store, have used, export, transport, distribute,
promote, market or have sold or otherwise dispose of a licensed product or
process.

     1.11 "EXPLOITATION" shall mean the making, having made, importation, use,
sale, offering for sale of a licensed product or process, including the
research, development, registration, modification, improvement, manufacture,
storage, optimization, import, export, transport, distribution, promotion,
marketing, sale or other disposition of a licensed product or process.

     1.12 "FDA" shall mean the United States Food and Drug Administration, or
any successor agency responsible for the evaluation and approval of
pharmaceutical products.

     1.13 "FIELD OF USE" shall mean all commercial applications of buccal sprays
for the metered delivery of pharmaceutical materials for the treatment,
prevention, or diagnosis of diseases in non-human animals.

     1.14 "FIRST COMMERCIAL SALE" shall mean the first sale of the Licensed
Product in a country under this agreement in an arms' length transaction to an
unaffiliated third party.

     1.15 "IMPROVEMENT" shall mean any modification, variation or revision to an
apparatus, method, product or technology, or any discovery, technology, device,
process or formulation related to an apparatus, method, product or technology,
whether or not patented or patentable, including any enhancement in the
manufacture or steps or processes thereof, ingredients, preparation,
presentation, formulation, means of delivery, packaging or dosage of an
apparatus, method, product or technology, any discovery or development of any
new or expanded indications for an apparatus, method, product or technology, or
any discovery or development that improves the stability, safety or efficacy of
an apparatus, method, product or technology and which is necessary or useful to
commercialize the Licensed Process or Licensed product in the Field Improvement
shall not include those Improvements, inventions, conceptions, or reductions to
practice by Licensee that are applicable solely to the veterinary industry, or
which did not rely on Licensed Technology.

     1.16 "INADA" shall mean an investigational new animal drug application
filed with the FDA or any equivalent application required by any Regulatory
Authority for approval to commence testing a Licensed Product in animals.

     1.17 "INDEMNIFICATION CLAIM NOTICE" shall have the meaning set forth in
Article 10.3.1.

     1.18 "INDEMNIFIED PARTY" shall have the meaning set forth in Article
10.3.1.

                                       3
<PAGE>

     1.19 "INFRINGEMENT SUIT" shall have the meaning set forth in Article 6.9.2.

     1.20 "INFORMATION AND INVENTIONS" shall mean all technical, scientific and
other know-how and information, trade secrets, knowledge, technology, means,
methods, processes, practices, formulas, instructions, skills, techniques,
procedures, experiences, ideas, technical assistance, designs, drawings,
assembly procedures, computer programs, apparatuses, specifications, data,
results and other material, including pre-clinical and clinical trial results,
manufacturing procedures and test procedures and techniques, (whether or not
confidential, proprietary, patented or patentable) in written, electronic or any
other form now known or hereafter developed, and all Improvements, whether to
the foregoing or otherwise, and other discoveries, developments, inventions, and
other intellectual property (whether or not confidential, proprietary, patented
or patentable) relating to a Licensed Technology, Licensed Product or Licensed
Process.

     1.21 "JOINT PATENTS" shall mean the patents and patent applications jointly
invented and/or owned by Licensee and NovaDel that are filed during the Term.

     1.22 ."JOINT IMPROVEMENTS" shall be those Improvements (that include Joint
Patents and Joint Technology) that are made and owned together by NovaDel and
Licensee.

     1.23 "JOINT TECHNOLOGY" shall be Technology that is made and owned together
by NovaDel and Licensee.

     1.24 "LICENSED PROCESS" shall mean the proprietary buccal spray technology
for the delivery of active pharmaceutical compounds through the mucosal membrane
of the mouth or using an aerosol or pump spray device that is under the Control
of NovaDel as of the Effective Date and any Improvements thereto by NovaDel
during the term of this Agreement.

     1.25 "LICENSED PRODUCT(S)" shall mean buccal sprays for the metered
delivery of pharmaceutical products within the Field of Use.

     1.26 "LICENSED TECHNOLOGY" shall mean the NovaDel Patents and the NovaDel
Know-How and any Drug Master File or its equivalent submitted to a regulatory
agency by NovaDel, collectively, but only with respect to the Exploitation of
Licensed Products within the Field of Use.

     1.27 "LICENSED TRADEMARK" shall mean those Trademarks Controlled by NovaDel
as of the execution date and during the term of this agreement which cover
licensed products and such other Trademarks as may be designated by NovaDel in
writing from time to time, and any registrations of the foregoing and pending
applications relating thereto.

     1.28 "LICENSEE" shall mean The Veterinary Company, Inc., a Delaware
corporation.

     1.29 "MANUFACTURING AGREEMENT" shall mean the Manufacturing and Formulation
Agreement for clinical trial material referred to Article 3.1.

                                       4
<PAGE>

     1.30 MATERIAL IMPROVEMENT shall mean a Joint Patent which was not directly
envisioned or directly foreshadowed by NovaDel Patents as of the date of
execution of this Agreement.

     1.31 "MINIMUM FINANCING" shall mean [***].

     1.32 "NADA" shall mean any New Animal Drug Application (or an Abbreviated
New Animal Drug Application) filed pursuant to the requirements of the FDA, and
any equivalent application required by any Regulatory Authority for the
marketing, sale or use of the Licensed Products in the Territory.

     1.33 "NET SALES" shall mean, for any period, the gross amount invoiced by
Licensee and its Affiliates for the sale of Licensed Product by Licensee or any
of its Affiliates to Third Parties, less deductions for chargebacks, billing
errors, rejected goods, damaged goods and returns. Any of the deductions listed
above that involves a payment by Licensee or its Affiliates shall be taken as a
deduction in the calendar quarter in which the payment is accrued by such
entity. For purposes of determining Net Sales, a Licensed Product shall be
deemed to be sold when invoiced and a "sale" shall not include transfers, uses
or dispositions for promotional, pre-clinical, clinical, regulatory or
governmental purposes. For purposes of calculating Net Sales, sales between or
among Licensee or its Affiliates shall be excluded from the computation of Net
Sales, but sales by Licensee or its Affiliates to Third Parties shall be
included in the computation of Net Sales.

     1.34 "NOVADEL" shall have the meaning set forth in the preamble.

     1.35 "NOVADEL KNOW-HOW" shall mean all Information and Inventions
Controlled by NovaDel as of the Effective Date or, from time to time, during the
Term that (a) (i) are necessary for the use of the Licensed Process to Exploit
Licensed Products or (ii) relate to Improvements to the Licensed Product, during
the term of this Agreement and (b) are not generally known, but excluding any
Information and Inventions to the extent covered by or claimed by any NovaDel
Patents.

     1.36 "NOVADEL PATENTS" shall mean the Patents and patent applications that
NovaDel Controls (a) as of the Effective Date, (b) that are filed during the
Term by NovaDel and describe or claim the Licensed Process or Licensed Product
or its use or manufacture, (c) any Improvements to the Licensed Products or
Licensed Process that are conceived and reduced to practice during the term of
the Agreement or (d) any Patents owned or controlled by NovaDel that the
manufacturing, use, sale, or commercialization of a Licensed Product by the
Licensee or its Sublicensee would infringe upon but for this Agreement

     1.37 "PATENTS" shall mean (a) all patents and patent applications; (b) any
substitutions, divisions, continuations, continuations-in-part, reissues,
renewals, registrations, confirmations, re-examinations, extensions,
supplementary protection certificates and the like,

INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.

                                       5
<PAGE>

and any provisional applications, of any such patents or patent applications;
and (c) any foreign or international equivalent of any of the foregoing relating
to the Technology.

     1.38 "REGULATORY APPROVAL" shall mean any and all approvals (including
pricing and reimbursement approvals), licenses, registrations or authorizations
of any Regulatory Authority, necessary for the Exploitation of the Licensed
Products in a country in the Territory, including (a) any approval of any
Licensed Product (including any INADAs, NADAs, and supplements or amendments
thereto); (b) pre- and post-approval marketing authorizations for a Licensed
Product (including any prerequisite manufacturing approval or authorization
related thereto); (c) labeling approval for a Licensed Product; and (d)
technical, medical and scientific licenses.

     1.39 "REGULATORY AUTHORITY" shall mean any applicable supra-national,
federal, national, regional, state, provincial or local regulatory agencies,
departments, bureaus, commissions, councils or other government entities
regulating or otherwise exercising authority with respect to the Licensed
Technology or the Licensed Products in the Territory.

     1.40 "REGULATORY DOCUMENTATION" shall mean all applications, registrations,
licenses, authorizations and approvals (including all Regulatory Approvals), all
correspondence submitted to or received from Regulatory Authorities (including
minutes and official contact reports relating to any communications with any
Regulatory Authority), all supporting documents and all clinical studies and
tests, relating to any Licensed Products, and all data contained in any of the
foregoing, including all regulatory drug lists, advertising and promotion
documents, adverse event files and complaint files.

     1.41 "SUBLICENSEE" shall mean any Third Party to which Licensee grants a
sublicense pursuant to Article 2.

     1.42 "SUBLICENSING FEES" shall mean all non-royalty consideration of any
kind, including any fees, milestones or other payments (whether cash or non-cash
(which shall be valued at fair market value)), received by Licensee or any of
its Affiliates from any Sublicensee as a direct or indirect result of the grant
by Licensee or any of its Affiliates to any Sublicensee of a license under, or
the use by any such Sublicensee of, any of the Licensed Technology or Licensed
Trademarks, in excess of the payments to be paid pursuant to Articles 4.4 and
4.5.

     1.43 "TECHNOLOGY" shall mean buccal sprays for the metered delivery of
pharmaceutical products.

     1.44 "TERM" shall have the meaning set forth in Article 7.

     1.45 "TERRITORY" shall mean the entire world.

     1.46 "THIRD PARTY" shall mean any Entity other than NovaDel, Licensee and
their respective Affiliates.

     1.47 "THIRD PARTY CLAIM" shall have the meaning set forth in Article
10.3.2.

                                       6
<PAGE>

     1.48 "TRADEMARK" shall include any word, name, symbol, color, designation
or device or any combination thereof, including any trademark, trade dress,
brand mark, trade name, brand name, logo or business symbol.

     1.49 "VALID CLAIM" shall mean, with respect to a particular country, a
claim of a Patent in such country that (a) has not been revoked or held
unenforceable or invalid by a decision of a court or governmental agency of
competent jurisdiction from which no appeal can be taken or has been taken
within the time allowed for appeal, and (b) has not been abandoned, disclaimed,
denied or admitted to be invalid or unenforceable through reissue or disclaimer
or otherwise in such country, and (c) in the case of a patent application claim,
has not been pending for more than seven years.

                                    ARTICLE 2
                                 GRANT OF RIGHTS

     2.1 LICENSE GRANTS TO LICENSEE.

          2.1.1 Subject to Article 2.3 and the other terms and conditions of
    this Agreement, NovaDel hereby grants to Licensee and Licensee accepts, a
    non-transferable (except as provided in Article 12), sublicensable (only as
    provided in Article 2), royalty-bearing, exclusive right and license under
    the Licensed Technology, Improvements, Patents, Joint Technology, Joint
    Improvements and Joint Patents within the Field of Use to Exploit Licensed
    Products in the Territory, to the full end of the Term for which the
    Licensed Technology is licensed, unless sooner terminated as hereinafter
    provided. For purposes of clarity, the License granted hereunder shall in no
    way be interpreted to preclude NovaDel or any Affiliate, licensee or
    sub-licensee of the NovaDel Patents and/or Licensed Technology in
    pre-clinical animal testing of a compound ultimately intended for human use.

          2.1.2 Subject to Article 2.3 and the other terms and conditions of
    this Agreement, NovaDel hereby grants to Licensee and Licensee accepts, a
    non-transferable (except as provided in Article 12), sublicensable (only as
    provided in Article 2.5), royalty-bearing, non-exclusive right and license
    under the Licensed Trademarks for the sole purpose of using such Licensed
    Trademarks to market, distribute and sell the Licensed Products licensed
    under Article 2.1.1 in the Territory, to the full end of the Term for which
    the Licensed Products are licensed, unless sooner terminated as hereinafter
    provided.

          2.1.3 As partial consideration for the grant of this license, Licensee
    shall not enter into an Agreement to sell Licensed Products with a Third
    Party, that is a direct competitor of NovaDel, which develops, manufactures
    or sells buccal spray to treat animals without the consent of NovaDel for
    the term of this agreement.

          2.1.4 Neither Party shall take any action against a Third Party,
    including but not limited to bringing an infringement proceeding, pertaining
    to Joint Patents without the consent of the other Party, which shall not be
    unreasonably withheld.

                                       7
<PAGE>

     2.2 RETAINED RIGHTS. NovaDel retains all right, title and interest,
including the right to grant licenses to Third Parties, in and to the Licensed
Technology not specifically granted to the Licensee under this Agreement, other
than those rights Controlled or co-owned by Licensee. Licensee shall have no
rights, express or implied, with respect to the Licensed Technology or the
Licensed Trademarks, except as expressly set forth in Article 2, and Licensee
covenants to NovaDel that none of Licensee, its Affiliates or Sublicensees shall
use the Licensed Technology, directly or indirectly, for any purpose other than
in connection with the development or Exploitation of Licensed Products, or the
Licensed Trademarks, directly or indirectly, for any purpose other than the
Exploitation of Licensed Products hereunder.

     2.3 SUBLICENSES. Licensee shall have the right to grant sublicenses under
the grants in Article 2.1 to Third Parties pursuant to a separate written
agreement, subject to the following requirements and conditions:

          2.3.1 Within five (5) days after execution or receipt thereof, as
    applicable, Licensee shall provide NovaDel with a full and complete copy of
    each sublicense granted hereunder and shall deliver copies of all reports
    (including relating to royalties and other payments) received by Licensee
    from such Sublicensees.

          2.3.2 Termination of this Agreement by NovaDel pursuant to Article 8
    with respect to Licensee shall not terminate any sublicense granted by
    Licensee pursuant to this Article 2.3 with respect to a Sublicensee,
    provided that (a) such Sublicensee is not in breach of any provision of this
    Agreement; provided however, if Sublicensee is in breach, NovaDel shall give
    Licensee written notice of breach and 60 days to cure. In such case, NovaDel
    shall assume and perform all obligations of Licensee under the sublicense
    agreement.

          2.3.3 Licensee shall not grant a Sublicense to Joint Patents outside
    of the Field of Use without the consent of NovaDel. Licensee may grant a
    sublicense to Joint Patents in the Field.

                                    ARTICLE 3
                  DEVELOPMENT AND COMMERCIALIZATION ACTIVITIES

     3.1 DEVELOPMENT AND COMMERCIALIZATION. Licensee shall have the sole right
and obligation to develop and commercialize the Licensed Products in the
Territory. NovaDel shall perform or cause to be performed, on behalf of
Licensee, certain development activities in accordance with a Manufacturing
Agreement to provide Licensed Product for use in clinical trials. Within thirty
days of the execution of this Agreement, the parties hereto shall execute such
Manufacturing Agreement that is not inconsistent with the terms herein and which
shall govern the manufacture of Licensed Product for clinical trials.. The
Parties within sixty days of the execution of this Agreement shall execute a
Second Manufacturing Agreement for the production of Licensed Product for
commercial purposes. Except as set forth herein and in the Manufacturing
Agreements, Licensee shall be solely responsible for all costs and expenses in
connection with all development and commercialization activities.

                                       8
<PAGE>

     3.2 CANDIDATE COMMITTEE.

          3.2.1 FORMATION AND AUTHORITY OF CANDIDATE COMMITTEE. NovaDel and
    Licensee shall establish a candidate committee (the "Candidate Committee"),
    which shall approve the selection of each product candidate that Licensee
    intends to license under this Agreement. Upon approval of each product
    candidate, such compound shall be listed on Exhibit 3 to this Agreement as
    the Candidate Committee deems appropriate. The Candidate Committee may not
    unreasonably withhold consent to the Licensee to add a compound to Exhibit
    3. Each Party shall appoint an equal number of representatives with the
    requisite experience and seniority to enable them to make decisions on
    behalf of the Parties. From time to time, each Party may substitute its
    representatives on written notice to the other Party.

          3.2.2 PROCEDURAL RULES OF CANDIDATE COMMITTEE. The Candidate Committee
    shall meet prior to the commencement of the development of a product
    candidate or as otherwise agreed to by the Parties, at the offices of
    NovaDel. The Candidate Committee shall adopt such standing rules as shall be
    necessary for its work. A quorum of the Candidate Committee shall exist
    whenever there is present at a meeting at least one representative appointed
    by each Party. Members of the Candidate Committee may attend a meeting
    either in person or by telephone, video conference or similar means in which
    each participant can hear what is said by the other participants.
    Representation by proxy shall not be allowed. The Candidate Committee shall
    take action by unanimous consent of NovaDel and Licensee, with each such
    Party having a single vote, irrespective of the number of representatives
    actually in attendance at a meeting, or by a written resolution signed by
    the designated representatives of each of NovaDel and Licensee.

          3.2.3 DISPUTE RESOLUTION. If the Candidate Committee cannot, or does
    not, reach agreement on an issue, then either Party shall have the right to
    refer such issue to the Chief Executive Officers of the Parties who shall
    confer on the resolution of the issue in good faith. Any final decision
    mutually agreed to by the Chief Executive Officers of the Parties shall be
    in writing and shall be conclusive and binding on the Parties. If such
    officers are not able to agree on the resolution of an issue within twenty
    (20) days after such issue was first referred to them, then Chief Executive
    Officer of the Licensee shall have the sole right to choose a product
    candidate, and such product candidate shall be added to Exhibit 3 as a
    Designated Compound. Full consideration will be given to NovaDel's goodwill
    when making this decision for a product candidate under a good faith
    dispute.

          3.2.4 LIMITATIONS ON AUTHORITY OF CANDIDATE COMMITTEE. Each Party to
    this Agreement shall retain the rights, powers, and discretion granted to it
    under this Agreement, and no such rights, powers, or discretion shall be
    delegated to or vested in the Candidate Committee unless such delegation or
    vesting of rights is expressly provided for in this Agreement or the Parties
    expressly so agree in writing. The Candidate Committee shall not have the
    power to amend or modify this Agreement, which may only be amended or
    modified as provided in Article 17.4 .

                                       9
<PAGE>

     3.3 Formulation Activities NovaDel shall manufacture and supply Licensee
with Licensed Product for clinical development of the Licensed Product. As such
NovaDel shall present Licensee with a suitable formulation for a Designated
Compound approved by Candidate Committee no later than the targeted timeframes
for formulation of Designated Compound as presented in Exhibit 1. Furthermore,
the cost for development of such Designated Compound shall be determined by the
schedule of expenses presented in Exhibit 2 and the cost of all materials needed
to formulate the Designated Compound which shall include, but not exclusively;
active and inactive ingredients, components, bottles, caps etc. presented below
and. All such reasonable and customary costs shall be paid by [***]. NovaDel
shall formulate designated compounds sequentially while working solely in the
labs located at 31 State Highway 12, Flemington, NJ and shall formulate no more
than two designated compounds simultaneously when working at new labs at 25
Minneakoning Road, Flemington, NJ. The first formulation will begin on payment
of the upfront licensing fee as per 4.4.1. The new labs at 25 Minneakoning Road,
Flemington, NJ will be completed no later than nine months from Effective Date.

     3.4 NovaDel shall source the Designated Compound (i.e., active ingredient)
for the manufacture of the clinical trial formulation. Licensee shall have input
and shall be allowed to provide timely recommendations for potential sources of
such active ingredient. NovaDel shall take into consideration the timing and
cost of the material as well as the reliability of the supplier.

     3.5 REGULATORY APPROVALS. All INADAs, NADAs and other filings, applications
or requests pursuant to or in connection with the Regulatory Approvals required
to Exploit a Licensed Product shall be made in the name of [***].

     3.6 REGULATORY RECORDS. NovaDel and Licensee each shall maintain, or cause
to be maintained, records of its respective Development Activities in sufficient
detail and in good scientific manner appropriate for patent and regulatory
purposes, which shall be complete and accurate and shall fully and properly
reflect all work done and results achieved in the performance of its respective
Development Activities, and which shall be retained by such Party for at least
five (5) years after the termination of this Agreement, or for such longer
period as may be required by Applicable Law. Each Party shall have the right,
during normal business hours and upon reasonable notice, to inspect and copy any
such records.

     3.7 DEVELOPMENT AND USE OF TRADEMARKS. Licensee shall have the sole right
to determine the Trademarks to be used with respect to the Exploitation of the
Licensed Products on a worldwide basis, provided that the product labeling and
promotional materials disclose that the Licensed Products are delivered using
the Licensed Process and include the Licensed Trademarks.

     3.8 DILIGENCE OBLIGATIONS. Licensee shall use Commercially Reasonable
Efforts to (a) develop and commercialize the Licensed Products in the Territory
in accordance with the terms and conditions of this Agreement; (b) obtain
Regulatory Approval(s) with respect to each Licensed Product in the Territory;
and (c) thereafter diligently and aggressively Exploit

INFORMATION  MARKED  BY  [***]  HAS  BEEN  OMITTED  PURSUANT  TO A  REQUEST  FOR
CONFIDENTIAL  TREATMENT.  THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.

                                       10
<PAGE>

each Licensed Product in the Territory to maximize sales.  Licensee shall ensure
that any  Sublicense  be  terminable  at the option of the Licensee in the event
that a Sublicensee  fails to maintain  active,  diligent  marketing  efforts for
Licensed Product. NovaDel shall use Commercially Reasonable Efforts to formulate
and manufacture the Licensed  Products  requested by Licensee in accordance with
the terms and conditions of this Agreement.

     3.9 BREACH OF DILIGENCE OBLIGATIONS.

          3.9.1 NOTIFICATION AND MEETING. If at any time NovaDel has a
    reasonable basis to believe that Licensee is in breach of its obligations
    under Article 3.8 with respect to a country in the Territory, NovaDel shall
    notify Licensee thereof, specifying the basis for its belief, and the
    Parties shall meet within ten (10) days after such notice to discuss in good
    faith NovaDel's concerns and Licensee's activities with respect to the
    Licensed Products in such country.

          3.9.2 If at any time Licensee has a reasonable basis to believe that
    NovaDel is in breach of its formulation or manufacturing obligations under
    Article 3, Licensee shall provide NovaDel written notice thereof, specifying
    the basis for its belief, and the Parties shall meet within ten business
    days (10) days after such notice to discuss in good faith Licensee's
    concerns and NovaDel's activities with respect to such formulation or
    manufacturing activities. If the breach is due solely to a technical or
    scientific difficulty or to a situation that is not within the control of
    NovaDel, the Parties shall cooperate to address and overcome such
    difficulty, and Licensee shall agree to a reasonable extension to overcome
    such sole technical or scientific difficulty.

     3.10 RIGHT OF TERMINATION WITH RESPECT TO A LICENSED PRODUCT. If after good
faith discussions pursuant to Article 3.9, Licensee does not take reasonable
steps designed to rectify the breach of its obligations under Article 3.8 in
such country within sixty (60) days of meeting with NovaDel pursuant to Article
3.9.1 or, if such failure cannot be rectified within such sixty (60)-day period,
if Licensee does not commence actions to rectify such failure within such period
and thereafter diligently pursue such actions, the license grants to Licensee
under Article 2.1 with respect to such Licensed Product in such country shall
terminate. Upon the termination of Licensee's rights with respect to a Licensed
Product pursuant to the immediately preceding sentence, if NovaDel chooses,
Licensee (a) shall, and shall cause its Affiliates and Sublicensees to, promptly
disclose to NovaDel, in whatever form NovaDel may request, all Regulatory
Documentation in the possession or Control of Licensee, its Affiliates or
Sublicensees that relate to the Exploitation of such Licensed Product in such
country; provided that [***], (b) Licensee shall, and will hereby, grant, and
shall cause its Affiliates and Sublicensees to grant, to NovaDel, (i) in the
case of a Joint Patent that is not a Material Improvement, an exclusive,
transferable, sublicensable license to all of Licensee's respective rights,
titles and interests in and to any and all Joint Patents in the Field of Use in
the country at no additional cost; and in the case of a Joint Patent that is a
Material Improvement, an exclusive, transferable, fully sublicenseable license
in the Field of Use in that country under the same royalty and sublicense terms
and costs as Licensee is required to pay for NovaDel Patents under this

INFORMATION  MARKED  BY  [***]  HAS  BEEN  OMITTED  PURSUANT  TO A  REQUEST  FOR
CONFIDENTIAL  TREATMENT.  THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.

                                       11
<PAGE>

Agreement. ; and (ii) other Information in the possession or Control of
Licensee, its Affiliates or Sublicensees, in each case that relate to the
Exploitation of such Licensed Product in such country (the "Product-Related
Assets") and that solely relate to such country; provided that NovaDel reimburse
Licensee for the cost of such Information and as long as the transfer of
Information does not, in Licensee's reasonable opinion, place Licensee at a
competitive disadvantage in that or another country and solely to the extent
that the Product-Related Assets relate to such country and may be licensed or
transferred under the terms set out herein without a legal impediment.

     3.11 MANUFACTURING.

          3.11.1 Subject to Article 3, at Licensee's expense, NovaDel shall
    manufacture and supply Licensee with Licensed Product for clinical
    development of the Licensed Product not later than the timeframe given in
    Exhibit 1 pursuant to the clinical trial Manufacturing Agreement. The
    Manufacturing Agreement will include the following terms: (i) NovaDel shall
    present Licensee with a suitable formulation for a Designated Compound that
    delivers the target dosage(s) within the timeframe designated in Exhibit 1;
    and (ii) the cost of the clinical supplies to Licensee shall [***], and
    further provided that NovaDel shall return such capital, equipment upgrade
    or additional components to Licensee at the termination or expiration of
    this Agreement unless the parties agree that NovaDel shall retain such
    capital equipment or equipment upgrades on terms to be agreed between the
    parties.

          3.11.2 Following receipt of Regulatory Approval, NovaDel shall
    manufacture and supply Licensee with projected and approved needs for
    Licensed Product in the United States pursuant to the Second Manufacturing
    Agreement on commercially reasonable terms, which is intended to be [***]
    over the reasonable and competitive cost of manufacturing.

          3.11.3 The Manufacturing Agreements will provide among other things
    that in the event that Licensee enters into a Sublicense for a Licensed
    Product and such Sublicensee desires to obtain rights to manufacture such
    Licensed Product, then NovaDel will not unreasonably withhold its consent to
    transfer the manufacturing rights to such Sublicensee, provided that
    measures are incorporated into the sublicensing agreement to continue to
    safeguard the confidentiality of NovaDel Know-how and technology with
    respect to the Licensed Product.

          3.11.4 It is the intent of the Parties that NovaDel manufacture and
    supply Licensee with 100% of its needs for Licensed Product in the United
    States pursuant to the terms of the Manufacturing Agreement. Licensee shall
    provide NovaDel with projections of Licensees commercial need and
    commercially reasonable time to prepare and manufacture the commercial
    product. Notwithstanding anything herein to the contrary, in the event that
    NovaDel is unable or unwilling to provide clinical or commercial supply of
    Licensed Product within a reasonable period of time upon commercially
    reasonable terms, then Licensee shall be entitled to use an alternate

INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.

                                       12
<PAGE>

    manufacturing source.. NovaDel shall promptly establish a contingency
    manufacturing plan so that in the event that NovaDel cannot or does not
    want to manufacture the Licensed Product in a commercially timely manner.
    NovaDel shall advise Licensee of the identity of the contingency
    manufacturer and provide confirmation of the ability and willingness of
    that manufacturer to act as the contingency manufacturing source. In such
    event, Licensee shall use commercially reasonable efforts to ensure that
    any such alternate manufacturing source agree (a) to maintain in strictest
    confidence all information Controlled by NovaDel relating to the
    manufacture of the Licensed Product and the Licensed Technology

          3.11.5 NovaDel will promptly notify Licensee of its inability to
    manufacture and supply Licensed Product according to agreed commercial
    projections by the Parties. Such notification shall be within a reasonable
    time period so that Product and Technology transfer may occur to an
    alternative manufacturing facility without significant disruption to
    commercial supply.

          3.11.6 COMPLIANCE WITH APPLICABLE LAW. Both NovaDel and Licensee shall
    perform, or cause to be performed, any and all of its activities with
    respect to the Licensed Products in good scientific manner and in compliance
    in all material respects with all Applicable Law. NovaDel agrees that, at
    all times during the performance of the Development Activities, it will act
    in accordance with good manufacturing practices and all applicable laws,
    rules and regulations.

                                    ARTICLE 4
                        ROYALTIES AND OTHER CONSIDERATION

     4.1 EQUITY.  Simultaneously with the execution of this Agreement,  Licensee
shall issue to NovaDel 592,500 shares of its common stock,  par value $0.001 per
share (the "Common Stock")  representing 15% of the outstanding shares of Common
Stock of the  Company as of October  23,  2003.  NovaDel  represents  that it is
acquiring  the Common Stock for  investment  purposes  only,  for an  indefinite
period of time,  for its own  account,  not as a nominee  or agent for any other
Entity,  and not  with a view to the  sale or  distribution  of all or any  part
thereof,  and  NovaDel  has  no  present  intention  of  selling,  granting  any
participation  in, or otherwise  distributing,  any or all of the Common  Stock.
NovaDel does not have any contract,  undertaking,  agreement or arrangement with
any Entity to sell,  transfer or grant  participation  to such  person,  firm or
corporation, with respect to any or all of the Common Stock.

     4.2 ROYALTIES. As partial consideration for the rights, privileges and
licenses granted hereunder and the activities performed by NovaDel under the
Manufacturing Agreements, Licensee shall make the following payments to NovaDel:

                                       13
<PAGE>

          4.2.1 Licensee shall pay to NovaDel royalties in an amount equal to
    [***] percent ([***]) of worldwide aggregate Net Sales by Licensee or any
    Affiliate of Licensee of each Licensed Product during each calendar year.

          4.2.2 Licensee shall pay to NovaDel (1) [***] percent ([***]) of all
    royalties received by Licensee or its Affiliate from sales by any
    Sublicensee of Licensed Product unless Licensee is strictly passive with
    regard to the development and commercialization activities of such
    Sublicensee relating to the Licensed Product sublicensed, in which case
    Licensee shall pay NovaDel [***] percent ([***])of all royalties received by
    Licensee or its Affiliate from sales by any Sublicensee of Licensed Product.
    For the purpose of Article 4, Licensee is deemed passive if the Sublicense
    occurs within six months of the date of this Agreement, or if Licensee has
    not filed any Regulatory Documentation with an appropriate regulatory agency
    prior to entering into the Sublicense.

          4.2.3 Licensee shall pay to NovaDel [***] percent ([***]) of all
    Sublicensing Fees other than fees received by Licensee under 4.2.2 unless
    Licensee is strictly passive with regard to the development and
    commercialization activities of such Sublicensee relating to the Licensed
    Product sublicensed, in which case Licensee shall pay NovaDel [***] percent
    ([***]) of all Sublicense Fees received by Licensee or its Affiliate from
    sales by any Sublicensee of Licensed Product.

          4.2.4 ROYALTY TERM. Licensee's royalty obligations under Article 4.2
    shall terminate, on a country-by-country basis, with respect to each
    Licensed Product on the expiration date in such country of the last to
    expire of any issued NovaDel Patent that includes at least one Valid Claim
    covering the sale of such Licensed Product in such country. Upon termination
    of the royalty obligations under this Article 4.2 in a country, the license
    grants to Licensee in Article 2.1 shall be reduced in accordance with terms
    respect to such Licensed Product in Article 4.6.

     4.3 ROYALTY PAYMENTS. Royalties under Article 4.2.1 and sublicensing
royalties under 4.2.2 shall be payable to NovaDel on a quarterly basis, within
forty-five (45) days after the end of each calendar quarter; provided, however,
at the end of a calendar year Licensee shall determine the actual amounts owed
to NovaDel under Article 4.2.2 and any additional amounts owed to NovaDel for
the first three calendar quarters of such calendar year shall be paid with the
royalty payment for the last calendar quarter of such calendar year, and
provided further in the event that Licensee's payments for such calendar
quarters exceed the actual royalties owed for such calendar quarters, Licensee
shall have the right to offset such excess payments against the royalty payment
for the last calendar quarter of such calendar year. Only one royalty payment
will be due on Net Sales of a given Licensed Product even though the
manufacture, sale or use of such Licensed Product may be covered by more than
one intellectual property right in a country.

INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.

                                       14
<PAGE>

     4.4 LICENSEE FEES.

          4.4.1 Licensee shall pay to NovaDel [***] as an upfront licensing fee,
    payable within 10 Business Days of the first date on which the Licensee has
    received the Minimum Financing.

          4.4.2 Licensee shall pay to NovaDel [***] upon completion of the
    Company's first financing in excess of [***].

          4.4.3 Licensee shall pay NovaDel [***] promptly upon designation by
    the Candidate Committee of the First Designated Compound.

          4.4.4 Licensee shall pay NovaDel [***] promptly upon designation by
    the Candidate Committee of the Second Designated Compound.

          4.4.5 Licensee shall pay NovaDel [***] promptly upon designation by
    the Candidate Committee of the Third Designated Compound.

          4.4.6 Licensee shall pay NovaDel [***] promptly upon designation by
    the Candidate Committee of the Fourth Designated Compound.

          4.4.7 Licensee shall pay NovaDel [***] promptly upon designation by
    the Candidate Committee of each Additional Designated Compound.

     4.5 MILESTONE PAYMENTS. Licensee shall also pay to NovaDel the following
Milestone Payments:

          4.5.1 (a) [***] within five Business Days from the date on which the
    Licensee's first filed NADA is accepted for review by the FDA for the first
    Licensed Product containing the First Designated Compound;

          (b) [***] promptly upon the date on which the Licensee's first filed
      European Marketing Application for the first Licensed Product containing
      the First Designated Compound within the European Union is accepted for
      review by the appropriate Regulatory Authority

          (c) [***] promptly upon the date on which the Licensee's first filed
      NADA for the first Licensed Product containing the First Designated
      Compound is approved by the FDA;

          (d) [***] promptly upon the date on which the Licensee's first filed
      European Marketing Application for the first Licensed Product containing
      the First Designated Compound in any country within the European Union is
      approved by the appropriate Regulatory Authority.

INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.

                                       15
<PAGE>

          4.5.2 (a) [***] within five Business Days from the date on which the
    Licensee's first filed NADA is accepted for review by the FDA for the
    Licensed Product containing the Second Designated Compound;

          (b) [***] promptly upon the date on which the Licensee's first filed
      European Marketing Application for the Licensed Product containing the
      Second Designated Compound within the European Union is accepted for
      review by the appropriate Regulatory Authority

          (c) [***] promptly upon the date on which the Licensee's first filed
      NADA for the Licensed Product containing the Second Designated Compound is
      approved by the FDA;

          (d) [***] promptly upon the date on which the Licensee's first filed
      European Marketing Application for the Licensed Product containing the
      Second Designated Compound in any country within the European Union is
      approved by the appropriate Regulatory Authority.

          4.5.3 (a) [***] within five Business Days from the date on which the
    Licensee's first filed NADA is accepted for review by the FDA for the
    Licensed Product containing the Third Designated Compound;

          (b) [***] promptly upon the date on which the Licensee's first filed
      European Marketing Application for the Licensed Product containing the
      Third Designated Compound within the European Union is accepted for review
      by the appropriate Regulatory Authority

          (c) [***] promptly upon the date on which the Licensee's first filed
      NADA for the Licensed Product containing the Third Designated Compound is
      approved by the FDA;

          (d) [***] promptly upon the date on which the Licensee's first filed
      European Marketing Application for the Licensed Product containing the
      Third Designated Compound in any country within the European Union is
      approved by the appropriate Regulatory Authority; and

          4.5.4 (a) [***] within five Business Days from the date on which the
    Licensee's first filed NADA is accepted for review by the FDA for the first
    Licensed Product containing the Fourth Designated Compound;

          (b) [***] promptly upon the date on which the Licensee's first filed
      European Marketing Application for the Licensed Product containing the
      Fourth Designated Compound within the European Union is accepted for
      review by the appropriate Regulatory Authority

INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.

                                       16
<PAGE>

          (c) [***] promptly upon the date on which the Licensee's first filed
      NADA for the Licensed Product containing the Fourth Designated Compound is
      approved by the FDA;

          (d) [***] promptly upon the date on which the Licensee's first filed
      European Marketing Application for the Licensed Product containing the
      Fourth Designated Compound in any country within the European Union is
      approved by the appropriate Regulatory Authority; and

          4.5.5 (a) [***] within five Business Days from the date on which the
    Licensee's first filed NADA is accepted for review by the FDA for the
    Licensed Product containing each Additional Designated Compound;

          (b) [***] promptly upon the date on which the Licensee's first filed
      European Marketing Application for the first Licensed Product containing
      each Additional Designated Compound within the European Union is accepted
      for review by the appropriate Regulatory Authority

          (c) [***] promptly upon the date on which the Licensee's first filed
      NADA for the Licensed Product containing each Additional Designated
      Compound is approved by the FDA;

          (d) [***] promptly upon the date on which the Licensee's first filed
      European Marketing Application for the first Licensed Product containing
      each Additional Designated Compound in any country within the European
      Union is accepted for review by the appropriate Regulatory Authority; and

     4.6 REDUCTION OF PAYMENTS. In the event that, or from and after the date on
which, (a) no Valid Claim of a NovaDel Patent covering a Licensed Product exists
in a country and (b) no regulatory exclusivity with respect to such Licensed
Product exists in such country (whether as a result of expiration of the
exclusivity period or otherwise), (i) the milestone payments set forth in
Article 4.5 with respect to such Licensed Product, if any, and (ii) the royalty
rate payable to NovaDel by Licensee under Article 4.2 with respect to sales of
such Licensed Product in such country, each shall be reduced by [***] percent
([***]).

     4.7 MODE OF PAYMENT. All payments to NovaDel under this Agreement shall be
paid in United States Dollars to a bank account in the United States as NovaDel
may reasonably designate. Any withholding taxes which Licensee, its Affiliates
or any Sublicensee shall be required by applicable law to withhold on remittance
of the payments shall be deducted from such payment to NovaDel and remitted to
the appropriate Regulatory Authority. Licensee shall furnish NovaDel with the
original copies of all official receipts for such taxes. If any currency
conversion shall be required in connection with the payments hereunder, such

INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.

                                       17
<PAGE>

conversion shall be made by using the average of the exchange rates prevailing
at Citibank, N.A. in New York, New York on the first business day of each month
in the reporting period to which such payments relate.

     4.8 NON-REFUNDABLE, NON-CREDITABLE. The amounts paid or payable under this
Article 4 shall be non-refundable and non-creditable against any other amounts
due NovaDel under this Agreement.

                                    ARTICLE 5
                               REPORTS AND RECORDS

     5.1 RECORD RETENTION. Licensee shall maintain (and shall ensure that its
Affiliates and Sublicensees shall maintain) complete and accurate books, records
and accounts that fairly reflect their respective Net Sales, Other Income and
any milestones payable with respect to Licensed Products in sufficient detail to
confirm the accuracy of any payments required hereunder and in accordance with
GAAP, which books, records and accounts shall be retained by Licensee until the
later of (a) three (3) years after the end of the period to which such books,
records and accounts pertain, and (b) the expiration of the applicable tax
statute of limitations (or any extensions thereof), or for such longer period as
may be required by Applicable Law.

     5.2 AUDIT. NovaDel shall have the right to have an independent certified
public accounting firm of nationally recognized standing, reasonably acceptable
to Licensee, to have access during normal business hours, and upon reasonable
prior written notice, to such of the records of Licensee (and its Affiliates and
Sublicensees) as may be reasonably necessary to verify the accuracy of such Net
Sales, Milestone Payments or Sublicense Fees for any calendar quarter ending not
more than thirty-six (36) months prior to the date of such request; provided,
however, that NovaDel shall not have the right to conduct more than one such
audit in any twelve (12)-month period. The accounting firm shall disclose to
each Party whether such Net Sales, Other Income or milestone payments are
correct or incorrect and the specific details concerning any discrepancies.
NovaDel shall bear the cost of such audit unless the audit reveals an
under-reporting or underpayment in excess of the greater of one hundred thousand
dollars ($150,000) or two percent (2%) of royalties, Milestone Payments or
Sublicense Fees payable for such period, in which case Licensee shall bear the
cost of the audit, rectify such underpayment and pay NovaDel applicable interest
as required by Article 5.5. All payments required under this Article 5.2 shall
be due within thirty (30) days of the date NovaDel provides Licensee notice of
the payment due. The results of such accounting firm shall be final, absent
manifest error.

     5.3 REPORTS. Within thirty (30) days of the end of each quarter of each
calendar year, Licensee shall deliver to NovaDel complete and accurate reports,
giving such particulars of the business conducted by Licensee during the
preceding quarter under this Agreement as shall be pertinent to an accounting
for royalties, milestone payments and Other Income hereunder. These shall
include at least the following:

          5.3.1 All Licensed Products used, leased or sold, by or for Licensee
    or its Affiliates.

                                       18
<PAGE>

          5.3.2 Total amounts invoiced for Licensed Products used, leased or
    sold, by or for Licensee or its Affiliates.

          5.3.3 Deductions applicable in computed "Net Sales" as defined in
    Article 1.33.

          5.3.4 Total milestone payments due based on achievement of milestones.

          5.3.5 Total Sublicense Fees owed by License from its Sublicensees.

          5.3.6 Total royalties due based on Net Sales by or for Licensee or its
    Affiliates and Sublicensing Fees owed by its Sublicensees, including any
    adjustments pursuant to Article 4.3.

          5.3.7 Names and addresses of all Sublicensees and Affiliates of
    Licensee.

     5.4 FINANCIAL STATEMENTS. Within one hundred twenty (120) days of the end
of each fiscal year of Licensee, Licensee shall provide NovaDel with a copy of
Licensee's audited financial statements for such year to NovaDel.

     5.5 INTEREST. Amounts which are not paid when due and which are not the
subject of a bona fide dispute shall accrue interest from the due date until
paid, at a rate equal to the then prevailing prime rate of Citibank, N.A., plus
four percent (4%), but in no event exceeding the amount permitted by applicable
law.

     5.6 CONFIDENTIALITY. Each report received by NovaDel shall be treated by
NovaDel as if it were "Confidential Information" subject to the terms of Article
16.

                                    ARTICLE 6
                              PATENT AND TRADEMARK
                           PROSECUTION AND MAINTENANCE

     6.1 OWNERSHIP OF INFORMATION AND INVENTIONS. Subject to Article 6.2 and the
license grants under Article 2, as between the Parties, each Party shall own and
retain all right, title and interest in and to any and all Information and
Inventions that are conceived, discovered, developed or otherwise made by or on
behalf of such Party (or its Affiliates or its Sublicensees (other than the
other Party and its Affiliates)), whether or not patented or patentable, and any
and all Patent and other intellectual property rights with respect thereto.
Subject to the license grants to Licensee under Article 2, as between the
Parties, NovaDel shall own and retain all right, title and interest in and to
all Licensed Technology other than Joint Technology, Joint Improvements and
Joint Patents, which shall be owned jointly by NovaDel and Licensee.

     6.2 OWNERSHIP OF THE LICENSED PROCESS. Subject to the license grants to
Licensee under Article 2 and other than Joint Technology, Joint Improvements and
Joint Patents, as between the Parties, NovaDel shall own and retain all right,

                                       19
<PAGE>

title and interest in and to the Licensed Process, including any and all
Information and Inventions with respect to the Licensed Process (including any
Improvements thereto) that are conceived, discovered, developed or otherwise
made, by or on behalf of NovaDel, its Affiliates or Sublicensees, whether or not
patented or patentable, and any and all Patent and other intellectual property
rights with respect thereto. Licensee acknowledges and agrees that the licenses
granted to it pursuant to Article 2.1 permit Licensee to use the Licensed
Process solely for the Exploitation of Licensed Products as provided in this
Agreement.

     6.3 OWNERSHIP OF JOINT TECHNOLOGY, JOINT IMPROVEMENTS AND JOINT PATENTS
Subject to Article 6.2 and the license grants under Article 2, NovaDel and
Licensee shall co-own any and all (a) Information and Inventions, conceived,
discovered, developed or otherwise made, jointly by or on behalf of NovaDel (or
its Affiliates or its sublicensees), on the one hand, and Licensee (or its
Affiliates or Sublicensees), on the other hand, in connection with the work
conducted under or in connection with this Agreement, whether or not patented or
patentable. NovaDel shall have the responsibility to file, prosecute and
maintain all Patents derived from Joint Technology if the Joint Technology can
be adapted to both human and veterinary uses, and Licensee shall have the
responsibility to file, prosecute and maintain all Patents on Joint Technology
directed exclusively to veterinary uses. Each Party shall keep the other
reasonably informed about the status of the Joint Patents according to Article
6.6 and shall prosecute such Joint Patents with the goal of maximizing the value
for both parties. Neither party shall enter into litigation on a Joint Patent
without the consent and participation of the other, as further defined in
Articles 6.7 and 6.8, unless required by law or court order.

     6.4 ALLOCATION OF OWNERSHIP INTEREST IN JOINT TECHNOLOGY, JOINT
IMPROVEMENTS AND JOINT PATENTS. NOVADEL SHALL OWN THE EXCLUSIVE INTEREST IN
HUMAN APPLICATIONS AND LICENSEE SHALL OWN THE EXCLUSIVE INTEREST IN NON-HUMAN
APPLICATIONS OF JOINT TECHNOLOGY, JOINT IMPROVEMENTS, AND JOINT PATENTS.

     6.5 OWNERSHIP OF LICENSED TRADEMARKS. Subject to the license grants under
Article 2, as between the Parties, NovaDel shall own and retain all right, title
and interest in and to the Licensed Trademarks. NovaDel hereby acknowledges and
affirms (a) that to the best of its knowledge, the Licensed Trademarks and the
registrations thereof are valid and (b) that NovaDel or its Affiliates, as the
case may be, are the owners of all right and title to and interest in the
Licensed Trademarks and the registrations thereof, including any form or
embodiment thereof, and the goodwill now and hereafter associated with the
Licensed Trademarks. Licensee (on its own behalf and on behalf of its
Affiliates) expressly disclaims any right or title to or interest in the
Licensed Trademarks and the registrations thereof, except for the license
granted in Article 2.1.2. Licensee hereby agrees and undertakes that it will
not, and it will cause its Affiliates not to, contest or dispute the validity
of, or the rights of NovaDel and its Affiliates, as the case may be, in and to,
the Licensed Trademarks, or any part thereof, or the registrations thereof, nor
knowingly impair or endanger the validity of any of the foregoing. Licensee
acknowledges that all use of the Licensed Trademarks by or on behalf of Licensee
or its Affiliates shall inure to the benefit of NovaDel and its Affiliates. Upon
termination of the license granted in Article 2.1.2, Licensee and its Affiliates
shall not be entitled to any compensation for any increase in the value of the
Licensed Trademarks or for any goodwill associated therewith. If so requested,
Licensee shall, and shall cause its Affiliates to, assist NovaDel and its
Affiliates to safeguard their full right, title and interest in and to the
Licensed Trademarks and the registrations thereof.

                                       20
<PAGE>

     6.6 UNITED STATES LAW. The determination of whether Information and
Inventions are conceived, discovered, developed or otherwise made by a Party for
the purpose of allocating proprietary rights (including Patent, copyright or
other intellectual property rights) therein, shall, for purposes of this
Agreement, be made in accordance with applicable United States law.

      6.7 PROSECUTION OF PATENTS AND TRADEMARKS.

          6.7.1 PROSECUTION OF NOVADEL PATENTS AND TRADEMARKS. NovaDel shall
    have the sole right, at its cost and expense, to obtain, prosecute and
    maintain throughout the world the NovaDel Patents and Licensed Trademarks.
    Licensee shall, and shall cause its Affiliates and Sublicensees, as
    applicable, to, cooperate fully with NovaDel in the preparation, filing,
    prosecution, and maintenance of NovaDel's Patents. Such cooperation includes
    (a) promptly executing all papers and instruments and requiring employees to
    execute such papers and instruments as reasonable and appropriate so as to
    enable NovaDel to file, prosecute, and maintain its Patents in any country;
    and (b) promptly informing NovaDel of matters that may affect the
    preparation, filing, prosecution, or maintenance of any such Patents.
    NovaDel shall provide Licensee with drafts of all patent applications and
    other material submissions to and correspondence with any patent authorities
    to the extent such applications or submissions relate to the Licensed
    Technology, in sufficient time, but in any event not less than ten (10) days
    prior to the date a reply is required by the relevant patent authorities, to
    allow for review and comment by Licensee. In addition, NovaDel shall provide
    Licensee with an opportunity to consult with NovaDel regarding the filing
    and contents of any such application, submission or correspondence. If
    Licensee provides to NovaDel comments with respect to any such application,
    submission or correspondence, to the extent such comments relate to any
    Licensed Technology, NovaDel agrees to reasonably consider such comments, it
    being understood that NovaDel retains the right to determine whether to
    comply with or incorporate such comments, if at all. If NovaDel elects not
    to pursue the filing, prosecution or maintenance of a NovaDel Patent in a
    particular country, or to take any other action with respect to a NovaDel
    Patent in a particular country that is necessary or useful to establish or
    preserve rights with respect to the Licensed Products or Processes, then
    NovaDel shall so notify Licensee promptly in writing and in good time to
    enable Licensee to meet any deadlines by which an action must be taken to
    establish or preserve any such rights in such NovaDel Patent in such
    country. Upon receipt of any such notice by NovaDel or if, at any time,
    NovaDel fails to initiate any such action within thirty (30) days after a
    request by Licensee that it do so (and thereafter diligently pursue such
    action), Licensee shall have the right, but not the obligation, to pursue
    the filing or registration, or support the continued prosecution or
    maintenance, of such NovaDel Patent at its expense in such country. If
    Licensee elects to pursue such filing or registration, as the case may be,
    or continue such support, NovaDel shall assign such NovaDel Patent to
    Licensee at no additional consideration.

          6.7.2 PROSECUTION OF JOINT PATENTS The party having the responsibility
    to file, prosecute and maintain Joint Patents under Article 6.3 shall comply
    with the procedure set out in Article 6.6.1, and the other Party shall
    cooperate as set out in Article 6.6.1.

                                       21
<PAGE>

     6.8 ENFORCEMENT OF PATENTS AND TRADEMARKS.

          6.8.1 INFRINGEMENT OF NOVADEL OR JOINT TECHNOLOGY AND TRADEMARKS. If
    either Party determines that any Technology or Trademark of NovaDel or any
    Joint Technology is being infringed by a Third Party's activities and that
    such infringement could affect the exercise by the Parties of their
    respective rights and obligations under this Agreement, it shall promptly
    notify such other Party in writing and provide such other Party with any
    evidence of such infringement that is reasonably available. Promptly after
    the receipt of such written notice, the Parties shall meet and discuss in
    good faith the removal of such infringement. NovaDel shall consider in good
    faith any comments from Licensee and shall keep Licensee reasonably informed
    of any steps taken to stop such infringement. NovaDel shall have the first
    right, but not the obligation, to stop such infringement at its sole cost
    and expense; provided, however, that Licensee shall reimburse NovaDel for
    [***] incurred by NovaDel with respect to actions taken to stop the
    infringement of Joint Patents or NovaDel Patents to the extent that such
    infringement would be a Licensed Product if sold by Licensee. In the event
    that NovaDel fails within ninety (90) days following notice of such
    infringement, or earlier notifies Licensee in writing of its intent not, to
    take commercially appropriate steps to remove any infringement of any
    NovaDel Patent or Licensed Trademark that is likely to have a material
    adverse effect on the sale of a Licensed Product, Licensee shall have the
    right to do so at Licensee's expense; provided, however, that if NovaDel has
    commenced negotiations with an alleged infringer for discontinuance of such
    infringement within such ninety (90) day period, NovaDel shall have an
    additional ninety (90) days to conclude its negotiations before Licensee may
    bring suit for such infringement, and provided further that Licensee shall
    not enter into any settlement or compromise with respect to any NovaDel
    Patent or Licensed Trademark without NovaDel's prior consent, which consent
    shall not be unreasonably withheld, and further provided that NovaDel shall
    not enter into a settlement or compromise of such infringement without
    Licensee's consent, which shall not be unreasonably withheld. Each Party
    shall provide reasonable assistance to the other Party, including providing
    access to relevant documents and other evidence, making its employees
    available at reasonable business hours, and joining the action to the extent
    necessary to allow the enforcing Party to maintain the action. Any amounts
    recovered by a Party pursuant to this Article, whether by settlement or
    judgment, shall be used to reimburse the Parties for their reasonable costs
    and expenses in making such recovery (which amounts shall be allocated pro
    rata if insufficient to cover the totality of such expenses), with any
    remainder being retained by the Party that brought the enforcement action;
    provided, however, that to the extent that any award is attributable to the
    loss of sales of Licensed Products, such amount shall be paid to Licensee
    and shall be treated as Net Sales on which royalties shall be due under
    Article 4.

     6.9 POTENTIAL THIRD PARTY RIGHTS.

     6.9.1 THIRD-PARTY LICENSES. If (a) in the opinion of Licensee,

INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.

                                       22
<PAGE>

    Licensee, or any of its Affiliates or Sublicensees, cannot Exploit a
    Licensed Product in a country in the Territory without infringing one or
    more Patents that have issued to a Third Party in such country, or (b) as
    a result of any claim made against a Party, or any of its Affiliates or
    Sublicensees, alleging that the Exploitation of a Licensed Product
    infringes or misappropriates any Patent or any other intellectual property
    right of a Third Party in a country in the Territory, a suit is brought in
    a court of competent jurisdiction, Licensee shall have the first right,
    but not the obligation to negotiate and to obtain a license from such
    Third Party as necessary for the Exploitation of any Licensed Products
    hereunder in such country. Licensee shall be solely responsible for [***]
    percent ([***]) of all royalty and other obligations with respect to the
    Exploitation of Licensed Products; provided, however, that Licensee shall
    have the right to credit [***] percent ([***]) of any royalties and other
    payments paid by Licensee, its Affiliates or Sublicensees under such
    license with respect to such country against the royalty payments or other
    payments to be paid by Licensee to NovaDel with respect to the sale of the
    Licensed Product(s) in that country ; provided, however, that no royalty
    or other payment when due, regardless of the amount or number of credits
    available to Licensee in accordance with this Agreement, shall be reduced
    by more than [***] percent ([***]) of the amounts otherwise owed in any
    calendar quarter. Credits not exhausted in any calendar quarter may be
    carried into future calendar quarters. Licensee agrees not to make
    statements against the interest of NovaDel or Joint Patents or reach
    written conclusions regarding the validity or enforceability of NovaDel or
    Joint Patents in any settlement agreement without the consent of NovaDel.
    . NovaDel agrees not to make statements against the interest of NovaDel or
    Joint Patents or reach written conclusions regarding the validity or
    enforceability of NovaDel or Joint Patents in any settlement agreement
    without the consent of Licensee.

          6.9.2 THIRD PARTY LITIGATION. In the event that a Third Party
    institutes a Patent, Trademark or other infringement suit (including any
    suit alleging the invalidity or unenforceability of the Patents of a Party
    or its Affiliates, or claiming confusion, deception or dilution of a
    Trademark) against either Party or its respective Affiliates, licensees or
    Sublicensees during the Term, alleging use of the Licensed Technology,
    Licensed Trademarks or any other activities hereunder, infringes one or more
    Patent, Trademark or other intellectual property rights held by such Third
    Party (an "Infringement Suit"), the Parties shall cooperate with one another
    in defending such suit. If NovaDel is named as a party to the litigation,
    and NovaDel determines that issues raised in the litigation adversely impact
    NovaDel Patents or Joint Patents, NovaDel shall have the right, not he
    obligation, to control that aspect of the litigation. Licensee shall
    cooperate with NovaDel in the defense of that aspect of the litigation. If
    NovaDel is not named as a party to the litigation and is not added as a
    party to the litigation, however, NovaDel determines that issues raised in
    the litigation adversely impact NovaDel Patents or Joint Patents, NovaDel
    shall have the right to consult with Licensee in the presentation of the
    defense. Licensee shall bear [***] percent ([***]) of its own costs and
    expenses associated with any such Infringement Suit to the extent that it
    relates to

INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.

                                       23
<PAGE>

    the Exploitation of any Licensed Product, and NovaDel shall bear [***]
    percent ([***]) of its own costs of cooperation and participation. If
    Licensee elects not to defend the Third Party Litigation, and NovaDel is
    named as a party to the litigation, NovaDel shall have the right, but not
    the responsibility, to do so at its own expense. In such case, Licensee
    shall bear [***] percent ([***]) of its own costs of cooperation and
    participation.

          6.9.3 RETAINED RIGHTS. Nothing in this Article 6.8 shall prevent
    Licensee, at its own expense, from obtaining any license or other rights
    from Third Parties it deems appropriate in order to permit the full and
    unhindered exercise of its rights under this Agreement.

                                   ARTICLE 7
                              TERM OF THE AGREEMENT

     7.1 TERM. Unless otherwise terminated pursuant to Article 8, this Agreement
shall enter into effect on the Effective Date and shall remain in full force and
effect on a country-by-country basis until the later of (a) the expiration date
of the last to expire of any issued NovaDel Patent that includes at least one
Valid Claim and (b) the twentieth (20th) anniversary of the Effective Date.
After such termination, Licensee shall have the full right to exploit the
Licensed Products and Licensed Processes without any further payments or
responsibility to NovaDel.

                                    ARTICLE 8
                                   TERMINATION

     8.1 TERMINATION UPON INSOLVENCY. If Licensee shall become bankrupt, or
shall file a petition in bankruptcy or insolvency or for reorganization or for
an arrangement or for the appointment of a receiver or trustee or of its assets,
or if an involuntary petition for any of the foregoing shall be filed with
respect to Licensee and not dismissed within sixty (60) days, or if the business
of Licensee shall be placed in the hands of a receiver, assignee or trustee for
the benefit of creditors, whether by the voluntary act of Licensee or otherwise,
this Agreement shall automatically terminate.

     8.2 TERMINATION FOR PAYMENT DEFAULT. Should Licensee fail to make payment
to NovaDel of royalties or other amounts due in accordance with the terms of
this Agreement in a country, NovaDel shall have the right to terminate this
Agreement in that country within sixty (60) days after giving written notice of
termination unless Licensee shall pay to NovaDel, within the 60-day period, all
such amounts due and payable. Upon the expiration of the 60-day period, if
Licensee shall not have paid all such amounts due and payable, the rights,
privileges and licenses granted hereunder shall, at the option of NovaDel,
immediately terminate. In the event a payment is the subject of a bona fide
dispute between NovaDel and Licensee that

INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.

                                       24
<PAGE>

is being pursued by a Party pursuant to the dispute resolution mechanism in
Article 9, then Licensee shall make such payment into an interest bearing escrow
account, and shall provide NovaDel with written notice that such payment is
being made into escrow subject to the outcome of such pending dispute resolution
procedure. In the event such dispute is finally and conclusively resolved in
favor of NovaDel, Licensee shall release such payment to NovaDel with any
accrued interest.

     8.3 TERMINATION FOR MATERIAL BREACH. Upon any material breach or default of
this Agreement by either Party, other than as set forth in Article 8.1 or 8.2
above, the other Party shall have the right to terminate this Agreement and the
rights, privileges and licenses granted hereunder upon giving thirty (60) days
written notice to the breaching Party. Such termination shall become effective
upon the expiration of such thirty (60)-day period unless the breaching Party
shall have cured any such breach or default prior to the expiration of such
thirty (60) day period. If the purported breaching party disputes that a breach
has occurred, the dispute shall be settled according to the procedure of Article
9 and the license agreement shall stay in effect during the dispute resolution
process.

     8.4 TERMINATION BY THE LICENSEE. The Licensee shall have the right at any
time to terminate this Agreement in whole or as to any Licensed Product by
giving ninety (90) days notice thereof in writing to NovaDel, provided that
Licensee satisfy any outstanding obligations to NovaDel.

     8.5 EFFECT ON JOINT PATENTS OF BREACH OR VOLUNTARY TERMINATION. If Licensee
breaches this Agreement which results in termination or Licensee voluntarily
terminates this Agreement, NovaDel shall have the right on written notice to
prohibit Licensee and its Affiliates from further commercialization of a
Licensed Product in a Joint Patent prior to the 20th anniversary of the
Effective Date of this Agreement. If NovaDel breaches this Agreement which
results in termination or NovaDel voluntarily terminates this Agreement,
Licensee shall have the right on written notice to prohibit NovaDel and its
Affiliates from commercialization of a Licensed Product in a Joint Patent prior
to the 20th anniversary of the Effective Date of this Agreement.

     8.6 FAILURE TO OBTAIN FINANCING. Notwithstanding anything to the contrary
herein, should Licensee fail to obtain the Minimum Financing by [***], NovaDel
shall have the right, which right shall continue until such time as Licensee
obtains the Minimum Financing, but not the obligation, to immediately terminate
this Agreement upon written notice to Licensee.

     8.7 SURVIVAL. Any expiration or termination of this Agreement shall not
affect the rights and obligations of the Parties accrued prior to such
expiration or termination. Without limiting the foregoing, Articles 5, 9, 10,
11, 14, 15 and 16 and Articles 8.5, 8.7, 8.8, 8.9, 17.1 and 17.7 shall survive
the termination or expiration of this Agreement for any reason. Further, all
obligations under Section 6 to cooperate on Joint Patents shall survive the
termination of this Agreement, including being named as a Party to a lawsuit at
the request of the other joint owner,at a minimum nominally participating in any
legal proceeding to protect, defend or assert that Joint Patent right, and
cooperating in the prosecution of the Joint Patents as necessary.

INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.

                                       25
<PAGE>

     8.8 WORK-IN-PROGRESS. Licensee and/or any Sublicensee thereof may, after
the effective date of a termination and continuing for a period not to exceed
six (6) months thereafter, sell all completed Licensed Products, and any
Licensed Products in the process of manufacture at the time of such termination,
and sell the same, provided that Licensee shall pay or cause to be paid to
NovaDel the royalties thereon as required by Article 4 of this Agreement and
shall submit the reports required by Article 5 hereof on the sales of Licensed
Products.

     8.9 RETURN OF INFORMATION; ASSIGNMENT AND LICENSE.

          8.9.1 Upon the termination of Licensee's rights with respect to a
    Licensed Product prior to the natural expiration date of this Agreement in a
    country, at NovaDel's choice, Licensee (a) shall, and shall cause its
    Affiliates and Sublicensees to, promptly disclose to NovaDel, in whatever
    form NovaDel may request, all Regulatory Documentation in the possession or
    Control of Licensee, its Affiliates or Sublicensees that relate to the
    Exploitation of such Licensed Product in such country; provided that NovaDel
    reimburses Licensee for the cost of such submissions and Regulatory
    Documentation, including the cost of clinical trials and data and document
    assembly, (b) shall, and will hereby, grant, and shall cause its Affiliates
    and Sublicensees to grant, to NovaDel, (i) in the case of a Joint Patent
    that is not a Material Improvement, an exclusive, transferable,
    sublicensable license to all of Licensee's respective rights, titles and
    interests in and to any and all Joint Patents in the Field of Use in the
    country at no additional cost; and in the case of a Joint Patent that is a
    Material Improvement, an exclusive, transferable, fully sublicenseable
    license in the Field of Use in that country under the same royalty and
    sublicense terms and costs as Licensee is required to pay for NovaDel
    Patents under this Agreement; and (ii) other Information in the possession
    or Control of Licensee, its Affiliates or Sublicensees, in each case that
    relate to the Exploitation of such Licensed Product in such country (the
    "Product-Related Assets") and that solely relate to such country; provided
    that NovaDel reimburse Licensee for the cost of such Information and as long
    as the transfer of Information does not, in Licensee's reasonable opinion,
    place Licensee at a competitive disadvantage in that or another country and
    (c) to the extent that the Product-Related Assets do not solely relate to
    such country or may not be licensed or transferred under the terms set out
    herein due to a legal impediment, NovaDel and Licensee shall use best
    efforts to agree on an alternative plan that would substantially accomplish
    the rights and obligations described herein.

          8.9.2 Notwithstanding anything contained in Article 8.9 , in the event
    that any sublicense granted by Licensee survives pursuant to Article 2.3.2,
    the Sublicensee may retain (a) the information and materials identified in
    Article 8.6.1 that are rightfully in its possession and (b)
    Agreement-Related Assets, in each case until the termination of such
    sublicense, whereupon such Sublicensee shall return such materials to
    NovaDel.

     8.10 CUMULATIVE REMEDIES. The rights and remedies set forth in this Article
8 are cumulative and in addition to any other rights that may be available to
the Parties.

                                       26
<PAGE>

     8.11 NON-REFUNDABILITY OF MILESTONES AND DEVELOPMENT COSTS. Any and all
Milestone Payments made to NovaDel by Licensee under Article 4.5 of this
Agreement shall be non-refundable in the event of termination of this Agreement
by either party under any of the provisions of Article 8.

                                    ARTICLE 9
                                   ARBITRATION

     9.1 PROCEDURES. Any dispute other than a dispute pertaining to the validity
or enforceability of a patent arising from or relating to this Agreement shall
be determined before a tribunal of three arbitrators in New York, New York in
accordance with the Commercial Arbitration Rules of the American Arbitration
Association (the "AAA"). One arbitrator shall be selected by NovaDel, one
arbitrator shall be selected by Licensee and the third arbitrator shall be
selected by mutual agreement of the first two arbitrators or by the AAA, if the
arbitrators appointed by the Parties are unable to select a third arbitrator
within fifteen (15) days of their selection. This Agreement shall stay in effect
during the arbitration proceeding, and all rights and responsibilities of the
Parties shall be honored and complied with during this dispute resolution
period. The decision of the arbitration board shall be binding on both parties
and nonappealable.

     9.2 ARBITRATION SHALL BE HANDLED WITH DISPATCH The arbitration proceeding
shall be conducted in a manner that assure that it will be concluded within six
months after the selection of the three arbitrators. The time period for
arbitration may be extended by the agreement of both parties.

     9.3 PATENT DISPUTES. Any claim, dispute, or controversy concerning the
validity, enforceability, or infringement of any Patent (including NovaDel or
Joint Patents) shall be resolved in any court having jurisdiction thereof. In
the event that, in any arbitration proceeding, any issue shall arise concerning
the validity, enforceability, or infringement of any Patent contained in the
Patents licensed hereunder, the arbitrators shall, to the extent possible,
resolve all issues other than validity, enforceability, and infringement; in any
event, the arbitrators shall not delay the arbitration proceeding for the
purpose of obtaining or permitting either Party to obtain judicial resolution of
such issues, unless an order staying the arbitration proceeding shall be entered
by a court of competent jurisdiction. Neither Party shall raise any issue
concerning the validity, enforceability, or infringement of any patent contained
in the Patents in any proceeding to enforce any arbitration award hereunder, or
in any proceeding otherwise arising out of any such arbitration award.

     9.4 COSTS. The costs of such arbitration shall be borne proportionate to
the finding of fault as determined by the arbitration panel. Judgment on the
arbitration award may be entered by any court of competent jurisdiction.

                                   ARTICLE 10
                          INDEMNIFICATION AND INSURANCE

     10.1 INDEMNIFICATION OF NOVADEL. Licensee shall defend, indemnify and hold
NovaDel, its Affiliates, and their respective directors, officers, employees and
agents harmless from and against all liability, demands, damages, including

                                       27
<PAGE>

expenses or losses including death, personal injury, illness or property damage
(collectively, "Losses") arising directly or indirectly out of any: (a) breach
of this Agreement by Licensee, its Affiliates, Sublicensees or permitted assigns
or transferees; (b) actual or asserted violations of Applicable Law by Licensee,
its Affiliates, Sublicensees or permitted assignees or transferees; (c) use by
Licensee, its Affiliates, Sublicensees or permitted assignees or transferees of
the Licensed Technology, unless the loss at is a result or partial result of the
conduct of NovaDel, including in the manufacture of the Licensed Product or
production of adulterated Licensed Product; (d) Exploitation of the Licensed
Products by Licensee, its Affiliates, Sublicensees or permitted assignees or
transferees, , unless the loss at is a result or partial result of the conduct
of NovaDel, including in the manufacture of the Licensed Product and except for
those Losses for which NovaDel has an obligation to indemnify Licensee and its
Affiliates pursuant to Article 10.2, as to which Losses each Party shall
indemnify the other to the extent of their respective liability for the Losses.

     10.2 INDEMNIFICATION OF LICENSEE. NovaDel shall defend, indemnify and hold
Licensee, its Affiliates, and their respective directors, officers, employees
and agents harmless from and against all Losses arising directly or indirectly
out of any: (a) breach of this Agreement by NovaDel or its Affiliates; (b)
conduct of NovaDel, including in the manufacture of the Licensed Product or
production of adulterated Licensed Product; (b) actual or asserted violations of
Applicable Law by NovaDel or its Affiliates, except for those Losses for which
Licensee has an obligation to indemnify NovaDel and its Affiliates pursuant to
Article 10.1, as to which Losses each Party shall indemnify the other to the
extent of their respective liability for the Losses.

     10.3 INDEMNIFICATION PROCEDURE.

          10.3.1 NOTICE OF CLAIM. The indemnified Party shall give the
    indemnifying Party prompt written notice (an "Indemnification Claim Notice")
    of any Losses or discovery of fact upon which such indemnified Party intends
    to base a request for indemnification under Article 10.1 or Article 10.2,
    but in no event shall the indemnifying Party be liable for any Losses that
    result from any delay in providing such notice. Each Indemnification Claim
    Notice must contain a description of the claim and the nature and amount of
    such Loss (to the extent that the nature and amount of such Loss is known at
    such time). The indemnified Party shall furnish promptly to the indemnifying
    Party copies of all papers and official documents received in respect of any
    Losses. All indemnification claims in respect of a Party, its Affiliates or
    their respective directors, officers, employees and agents shall be made
    solely by such Party to this Agreement (the "Indemnified Party").

          10.3.2 THIRD PARTY CLAIMS. The obligations of an indemnifying Party
    under this Article 11 with respect to Losses arising from claims of any
    Third Party that are subject to indemnification as provided for in Articles
    10.1 or 10.2 (a "Third Party Claim") shall be governed by and be contingent
    upon the following additional terms and conditions:

          (a) CONTROL OF DEFENSE. At its option, the indemnifying Party may
      assume the defense of any Third Party Claim by giving written notice to
      the Indemnified Party within thirty (30) days after the indemnifying

                                       28
<PAGE>

      Party's receipt of an Indemnification Claim Notice. The assumption of the
      defense of a Third Party Claim by the indemnifying Party shall not be
      construed as an acknowledgment that the indemnifying Party is liable to
      indemnify any indemnified Party in respect of the Third Party Claim, nor
      shall it constitute a waiver by the indemnifying Party of any defenses it
      may assert against any indemnified Party's claim for indemnification. Upon
      assuming the defense of a Third Party Claim, the indemnifying Party may
      appoint as lead counsel in the defense of the Third Party Claim any legal
      counsel selected by the indemnifying Party. In the event the indemnifying
      Party assumes the defense of a Third Party Claim, the Indemnified Party
      shall immediately deliver to the indemnifying Party all original notices
      and documents (including court papers) received by any indemnified Party
      in connection with the Third Party Claim. Should the indemnifying Party
      assume the defense of a Third Party Claim, the indemnifying Party shall
      not be liable to the Indemnified Party or any other indemnified Party for
      any legal expenses subsequently incurred by such indemnified Party in
      connection with the analysis, defense or settlement of the Third Party
      Claim. In the event that it is ultimately determined that the indemnifying
      Party is not obligated to indemnify, defend or hold harmless an
      Indemnified Party from and against the Third Party Claim, the Indemnified
      Party shall reimburse the indemnifying Party for any and all costs and
      expenses (including attorneys' fees and costs of suit) and any Losses
      incurred by the indemnifying Party in its defense of the Third Party Claim
      with respect to such Indemnified Party.

          (b) RIGHT TO PARTICIPATE IN DEFENSE. Without limiting Article
      10.3.2(a), any Indemnified Party shall be entitled to participate in, but
      not control, the defense of such Third Party Claim and to employ counsel
      of its choice for such purpose; provided, however, that such employment
      shall be at the Indemnified Party's own expense unless (i) the employment
      thereof has been specifically authorized by the indemnifying Party in
      writing or (ii) the indemnifying Party has failed to assume the defense
      and employ counsel in accordance with Article 10.3.2(a) (in which case the
      Indemnified Party shall control the defense).

          (c) SETTLEMENT. With respect to any Losses relating solely to the
      payment of money damages in connection with a Third Party Claim and that
      will not result in the Indemnified Party's becoming subject to injunctive
      or other relief or otherwise adversely affect the business of the
      Indemnified Party in any manner, and as to which the indemnifying Party
      shall have acknowledged in writing the obligation to indemnify the
      Indemnified Party hereunder, the indemnifying Party shall have the sole
      right to consent to the entry of any judgment, enter into any settlement
      or otherwise dispose of such Loss, on such terms as the indemnifying
      Party, in its sole discretion, shall deem appropriate. With respect to all
      other Losses in connection with Third Party Claims, where the indemnifying
      Party has assumed the defense of the Third Party Claim in accordance with
      Article 10.3.2(a), the indemnifying Party shall have authority to consent
      to the entry of any judgment, enter into any settlement or otherwise
      dispose of such Loss provided it obtains the prior written consent of the
      Indemnified Party (which consent shall not be unreasonably withheld or
      delayed). The indemnifying Party shall not be liable for any settlement or

                                       29
<PAGE>

      other disposition of a Loss by an indemnified Party that is reached
      without the written consent of the indemnifying Party. Regardless of
      whether the indemnifying Party chooses to defend or prosecute any Third
      Party Claim, no indemnified Party shall admit any liability with respect
      to, or settle, compromise or discharge, any Third Party Claim without the
      prior written consent of the indemnifying Party.

          (d) COOPERATION. Regardless of whether the indemnifying Party chooses
      to defend or prosecute any Third Party Claim, the Indemnified Party shall,
      and shall cause each other indemnified Party to, cooperate in the defense
      or prosecution thereof and shall furnish such records, information and
      testimony, provide such witnesses and attend such conferences, discovery
      proceedings, hearings, trials and appeals as may be reasonably requested
      in connection therewith. Such cooperation shall include access during
      normal business hours afforded to indemnifying Party to, and reasonable
      retention by the Indemnified Party of, records and information that are
      reasonably relevant to such Third Party Claim, and making indemnified
      Parties and other employees and agents available on a mutually convenient
      basis to provide additional information and explanation of any material
      provided hereunder, and the indemnifying Party shall reimburse the
      Indemnified Party for all its reasonable out-of-pocket expenses in
      connection therewith.

          (e) EXPENSES. Except as provided above, the costs and expenses,
      including fees and disbursements of counsel, incurred by the Indemnified
      Party in connection with any claim shall be reimbursed on a calendar
      quarter basis by the indemnifying Party, without prejudice to the
      indemnifying Party's right to contest the Indemnified Party's right to
      indemnification and subject to refund in the event the indemnifying Party
      is ultimately held not to be obligated to indemnify the Indemnified Party.

     10.4 INSURANCE. Licensee shall have and maintain such type and amounts of
liability insurance covering the manufacture, supply, use and sale of the
Licensed Products as is normal and customary in the pharmaceutical industry
generally for parties similarly situated, and shall upon request provide NovaDel
with a copy of its policies of insurance in that regard, along with any
amendments and revisions thereto. NovaDel shall maintain such type and amounts
of liability insurance covering the manufacture, supply, use and sale of the
Licensed Products as is normal and customary in the pharmaceutical industry for
a manufacturer of products.

                                   ARTICLE 11
                         REPRESENTATIONS AND WARRANTIES;
                             LIMITATION OF LIABILITY

     11.1 REPRESENTATIONS, WARRANTIES AND COVENANTS. Each Party hereby
represents and warrants to the other Party as of the Effective Date as follows:

          11.1.1 DULY ORGANIZED. Such Party is a corporation duly organized,
    validly existing and in good standing under the laws of the state in which
    it is incorporated, and has full corporate power and

                                       30
<PAGE>

    authority and the legal right to own and operate its property and assets
    and to carry on its business as it is now being conducted and as is
    contemplated to be conducted by this Agreement.

          11.1.2 CORPORATE AUTHORITY. Such Party (a) has the power and authority
    and the legal right to enter into this Agreement and perform its obligations
    hereunder, and (b) has taken all necessary action on its part required to
    authorize the execution and delivery of this Agreement and the performance
    of its obligations hereunder. The Agreement has been duly executed and
    delivered on behalf of such Party and is enforceable against it in
    accordance with its terms, subject to the effects of bankruptcy, insolvency
    or other laws of general application affecting the enforcement of creditor
    rights and judicial principles affecting the availability of specific
    performance and general principles of equity, whether enforceability is
    considered in a proceeding at law or in equity.

          11.1.3 LITIGATION. Such Party is not aware of any pending or
    threatened litigation (and has not received any communication) that alleges
    that such Party's activities related to this Agreement have violated, or
    that by conducting the activities as contemplated herein such Party would
    violate, any of the intellectual property rights of any other Person.

          11.1.4 CONSENTS, APPROVALS, ETC. All necessary consents, approvals and
    authorizations of all regulatory and governmental authorities and other
    Persons required to be obtained by such Party in connection with the
    execution and delivery of this Agreement and the performance of its
    obligations hereunder have been obtained.

          11.1.5 CONFLICTS. The execution and delivery of this Agreement and the
    performance of such Party's obligations hereunder (a) do not conflict with
    or violate any requirement of applicable law or regulation or any provision
    of the articles of incorporation, bylaws, or any similar constitutive
    document of such Party, as applicable, in any material way, and (b) do not
    conflict with, violate, or breach or constitute a default or require any
    consent under, any contractual obligation or court or administrative order
    by which such Party is bound.

          11.1.6 ADDITIONAL REPRESENTATIONS AND WARRANTIES OF NOVADEL. NovaDel
    represents and warrants to Licensee that, to its Knowledge, as of the
    Effective Date, NovaDel is the owner or (sub)licensee (with the right to
    grant sublicenses to Licensee as contemplated under this Agreement) of the
    NovaDel Patents, and has all right, title, and interest in and to the
    NovaDel Patents, including exclusive, absolute, irrevocable right, title and
    interest thereto, free and clear of all liens, charges, encumbrances or
    other restrictions or limitations of any kind whatsoever and to the
    NovaDel's knowledge and belief there are no licenses, options, restrictions,
    liens, rights of third parties, disputes, royalty obligations, proceedings
    or claims relating to, affecting, or limiting its rights or the rights of
    the Licensee under this Agreement with respect to, or which may lead to a
    claim of infringement or invalidity regarding, any part or all of the
    Licensed Technology and their use as contemplated in the underlying patent
    applications as presently

                                       31
<PAGE>

    drafted. The NovaDel Patents have not, as of the Effective Date, been held
    by a court of competent jurisdiction to be invalid or unenforceable, in
    whole or in part.

          11.1.7 To NovaDel's knowledge and belief there is no claim, pending or
    threatened, of infringement, interference or invalidity regarding, any part
    or all of the Licensed Technology and their use as contemplated in the
    underlying patent applications as presently drafted.

     11.2 ADDITIONAL COVENANTS OF LICENSEE. Licensee on behalf of itself and its
Affiliates agrees and covenants to the extent permitted by applicable law,
never, in any country, region or jurisdiction in the Territory, to institute or
prosecute any claim, action or suit at law or in equity seeking to have any
claim in a NovaDel Patent declared invalid or unenforceable; provided, however,
that nothing contained herein shall prohibit Licensee and its Affiliates and
Sublicensees from either (a) asserting any and all defenses available to it,
including assertions relating to the validity or enforceability of the NovaDel
Patents, in any suit or proceeding brought against them alleging the
infringement of any of the NovaDel Patents or breach of contract, or (b)
asserting any and all defenses, evidence and arguments, including lack of
patentability of the subject matter of a count or claim and lack of support for
a count or claim, in any interference involving a patent or patent application
owned by Licensee or its Affiliates or Sublicensees and a patent or patent
application included within the definition of the NovaDel Patents. In its
agreements with each of its Sublicensees, Licensee shall include provisions
requiring a covenant, materially identical to that Licensee is making in this
Article 11.2, on the part of the Sublicensee, and shall provide that NovaDel
shall have march-in right to seek termination of such agreement in the event the
Sublicensee breaches the covenant. NovaDel's right to seek termination of such
agreement with the Sublicensee shall be subject to notice, cure and dispute
resolutions provisions materially identical to the provision set forth in
Articles 8 and 9. Licensee and its Affiliates will take all reasonable action
(including signing required documents) and offer full cooperation to allow
NovaDel to exercise the march-in rights provided herein, to the extent permitted
by law.

     11.3 NovaDel on behalf of itself and its Affiliates agrees and covenants to
the extent permitted by applicable law, never, in any country, region or
jurisdiction in the Territory, to institute or prosecute any claim, action or
suit at law or in equity seeking to have any claim in a Licensee Patent declared
invalid or unenforceable; provided, however, that nothing contained herein shall
prohibit NovaDel and its Affiliates and Sublicensees from either (a) asserting
any and all defenses available to it, including assertions relating to the
validity or enforceability of the Licensee Patents, in any suit or proceeding
brought against them alleging the infringement of any of the Licensee Patents or
breach of contract, or (b) asserting any and all defenses, evidence and
arguments, including lack of patentability of the subject matter of a count or
claim and lack of support for a count or claim, in any interference involving a
patent or patent application owned by NovaDel or its Affiliates or Sublicensees
and a patent or patent application included within the definition of the
Licensee Patents. In its agreements with each of its Sublicensees, NovaDel shall
include provisions requiring a covenant, materially identical to that NovaDel is
making in this Article, on the part of the Sublicensee, and shall provide that
Licensee shall have march-in right to seek termination of such agreement in the
event the Sublicensee breaches the covenant. Licensee's right to seek
termination of such agreement with the Sublicensee shall be subject to notice,
cure and dispute resolutions provisions materially identical to the provision
set forth in Articles 8 and 9. NovaDel and its Affiliates will take all

                                       32
<PAGE>

reasonable action (including signing required documents) and offer full
cooperation to allow Licensee to exercise the march-in rights provided herein,
to the extent permitted by law.

     11.4 DISCLAIMER OF WARRANTY. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN
ARTICLES 11.1 AND 11.2, NOVADEL MAKES NO REPRESENTATIONS AND GRANTS NO
WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY
STATUTE OR OTHERWISE, UNDER THIS AGREEMENT, AND NOVADEL SPECIFICALLY DISCLAIMS
ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING
ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR
PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE
NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES UNDER THIS
AGREEMENT.

     11.5 LIMITATION OF LIABILITY. NONE OF NOVADEL OR ANY OF ITS AFFILIATES
SHALL BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES
(INCLUDING FOR LOST PROFITS), WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE, TORT,
STRICT LIABILITY OR OTHERWISE, ARISING OUT OF (A) THE USE OF THE LICENSED
TECHNOLOGY OR LICENSED TRADEMARKS OR (B) ANY BREACH OF OR FAILURE TO PERFORM ANY
OF THE PROVISIONS OF THIS AGREEMENT.

                                   ARTICLE 12
                                   ASSIGNMENT

     This Agreement and the rights and duties appertaining hereto may not be
assigned by either Party without first obtaining the written consent of the
other which consent shall not be unreasonably withheld. Any such purported
assignment, without the prior written consent of the other Party, shall be null
and of no effect. Notwithstanding the foregoing, Licensee may assign this
Agreement to a purchaser, merging or consolidating corporation, or acquirer of
substantially all of Licensee's assets or business or pursuant to any
reorganization qualifying under Article 368 of the Internal Revenue Code of
1986, as amended, as may be in effect at such time.

                                   ARTICLE 13
                          PAYMENT OF FEES AND EXPENSES

     Each of Licensee and NovaDel shall be responsible for their own expenses
relating to the negotiation, execution and performance of this Agreement.

                                   ARTICLE 14
                          USE OF NAMES AND PUBLICATION

     14.1 USE OF NAME. Nothing contained in this Agreement shall be construed as
granting any right to Licensee, its Affiliates or Sublicensees to use in
advertising, publicity, or other promotional activities any Trademark of NovaDel
or any of its units (including contraction, abbreviation or simulation of any of

                                       33
<PAGE>

the foregoing) without the prior, written consent of NovaDel; provided, however,
that NovaDel acknowledges and agrees that Licensee may use the names of NovaDel
in various documents used by Licensee for capital raising and financing without
such prior written consent to the limited extent that such use may be required
by law, and provided further that all such uses shall be factually accurate and
not misleading.

     14.2 RELATIONSHIP OF THE PARTIES. Nothing herein shall be deemed to
establish a relationship of principal and agent between NovaDel and Licensee,
nor any of their agents or employees for any purpose whatsoever. This Agreement
shall not be construed as creating a partnership between NovaDel and Licensee,
or as creating any other form of legal association or arrangement which would
impose liability upon one Party for the act or failure to act of the other
Party.

     14.3 PUBLICATIONS. In the event that either Party desires to publish or
disclose, by written, oral or other presentation, Licensed Technology or any
material information related thereto, then that Party shall notify the other
Party in writing of its intention at least sixty (60) days prior to any speech,
lecture or other oral presentation and at least sixty (60) days before any
written or other publication or disclosure. The disclosing Party shall include
with such notice a description of any proposed oral presentation or, with
respect to any proposed written or other disclosure, a current draft of such
proposed disclosure or abstract. The non-disclosing Party may request that the
disclosing party, no later than thirty (30) days following the receipt of such
notice, delay such presentation, publication or disclosure in order to enable
the filing of a patent application, copyright or other appropriate form of
intellectual property protection related to the information to be disclosed.
Upon receipt of such request to delay such presentation, publication or
disclosure, the disclosing Party shall arrange for a delay of such presentation,
publication or disclosure until such time as the appropriate Party has filed, or
had filed on its behalf, such patent application, copyright or other appropriate
form of intellectual property protection in form and in substance reasonably
satisfactory to both Parties. If the disclosing Party does not receive any such
request to delay such presentation, publication or disclosure, the disclosing
Party may submit such material for presentation, publication or other form of
disclosure. Notwithstanding the foregoing, in no event shall the disclosing
Party have any right to publish or disclose the Licensed Process in the Field or
any information or data related thereto without the prior written consent of the
other Party, which consent the non-disclosing Party may not unreasonably
withhold.

                                   ARTICLE 15
                   PAYMENTS, NOTICES AND OTHER COMMUNICATIONS

     All notices or other communications that are required or permitted
hereunder shall be in writing and delivered personally, sent by telecopier (and
promptly confirmed by personal delivery, registered or certified mail or
overnight courier as provided herein), sent by nationally-recognized overnight
courier or sent by registered or certified mail, postage prepaid, return receipt
requested, addressed as follows:

                                       34
<PAGE>

                  If to NovaDel to:

                           NovaDel Pharma, Inc.
                           25 Minneakoning Rd., Suite 101
                           Flemington,, NJ  08822
                           Attention:  President
                           908.806.7624 (fax)

                  with a copy (not constituting notice) to:

                           Jones Day
                           222 East 41st Street
                           New York, New York  10017-6702
                           TEL: 1.212.326.3939
                           FAX: 1.212.755.7306

                  If to Licensee to:

                           The Veterinary Company, Inc.
                           The Veterinary Company, Inc.
                           201 Corporate Dr., Langhorne, PA 19047-8007
                           Attention:  President
                           Tel: 215-579-8335

                  with a copy(not constituting notice) to:

                           King & Spalding
                           191 Peachtree Street
                           Atlanta, Georgia 30303-1763
                           Attn: Sherry M. Knowles, Esq.
                           Tel: 404-572-3541
                           Fax: 404-572-5145

or to such other address as the Party to whom notice is to be given may have
furnished to the other Party in writing in accordance herewith. Any such
communication shall be deemed to have been given (a) when delivered, if
personally delivered or sent by telecopier on a business day, (b) on the
business day after dispatch, if sent by nationally-recognized overnight courier,
and (c) on the third business day following the date of mailing, if sent by
mail. It is understood and agreed that this Article 16 is not intended to govern
the day-to-day business communications necessary between the Parties in
performing their duties, in due course, under the terms of this Agreement.

                                   ARTICLE 16
                                 CONFIDENTIALITY

      16.1 DEFINITION. "Confidential Information" of a Party shall mean all
information and know-how and any tangible embodiments thereof provided by or on
behalf of such Party to the other Party either in connection with the

                                       35
<PAGE>

discussions and negotiations pertaining to, or in the course of performing, this
Agreement, including the terms of this Agreement; data; knowledge; practices;
processes; ideas; research plans; engineering designs and drawings; research
data; manufacturing processes and techniques; scientific, manufacturing,
marketing and business plans; and financial and personnel matters relating to
the disclosing Party or to its present or future products, sales, suppliers,
customers, employees, investors or business. For purposes of this Agreement,
notwithstanding the Party that disclosed such information or know-how, all
NovaDel Know-How and all Information and Inventions with respect to the Licensed
Process shall be Confidential Information of NovaDel.

     16.2 EXCLUSIONS. Notwithstanding the foregoing, information or know-how of
a Party shall not be deemed Confidential Information with respect to a receiving
Party for purposes of this Agreement if such information or know-how:

          16.2.1 was already known to the receiving Party or its Affiliates,
    other than under an obligation of confidentiality or non-use, at the time of
    disclosure to such receiving Party;

          16.2.2 was generally available or known to parties reasonably skilled
    in the field to which such information or know-how pertains, or was
    otherwise part of the public domain, at the time of its disclosure to such
    receiving Party;

          16.2.3 became generally available or known to parties reasonably
    skilled in the field to which such information or know-how pertains, or
    otherwise became part of the public domain, after its disclosure to such
    receiving Party through no fault of a Party other than the Party that
    Controls such information and know-how;

          16.2.4 was disclosed to such receiving Party or its Affiliates, other
    than under an obligation of confidentiality or non-use, by a Third Party who
    had no obligation to the Party that Controls such information and know-how
    not to disclose such information or know-how to others; or

          16.2.5 was independently discovered or developed by such receiving
    Party or its Affiliates, as evidenced by their written records, without the
    use of Confidential Information belonging to the Party that Controls such
    information and know-how, except with respect to the NovaDel Know-How with
    respect to the Licensed Process, which shall be and remain Confidential
    Information of NovaDel.

Specific aspects or details of Confidential Information shall not be deemed to
be within the public domain or in the possession of a Party merely because the
Confidential Information is embraced by more general information in the public
domain or in the possession of such Party. Further, any combination of
Confidential Information shall not be considered in the public domain or in the
possession of a Party merely because individual elements of such Confidential
Information are in the public domain or in the possession of such Party unless
the combination and its principles are in the public domain or in the possession
of such Party.

     16.3 DISCLOSURE AND USE RESTRICTION. Except as expressly provided herein,
the Parties agree that, for the Term and for five (5) years thereafter, each
Party and its Affiliates and sublicensees shall keep completely confidential and

                                       36
<PAGE>

shall not publish or otherwise disclose and shall not use for any purpose except
for the purposes contemplated by this Agreement any Confidential Information of
the other Party, its Affiliates or Sublicensees.

     16.4 AUTHORIZED DISCLOSURE. Each Party may disclose Confidential
Information of the other Party to the extent that such disclosure is:

          16.4.1 REQUIRED BY GOVERNMENTAL ORDER. Made in response to a valid
    order of a court of competent jurisdiction or other supra-national, federal,
    national, regional, state, provincial or local governmental or regulatory
    body of competent jurisdiction; provided, however, that such Party shall
    first have given notice to such other Party and given such other Party a
    reasonable opportunity to quash such order and to obtain a protective order
    requiring that the Confidential Information and documents that are the
    subject of such order be held in confidence by such court or agency or, if
    disclosed, be used only for the purposes for which the order was issued; and
    provided further that if a disclosure order is not quashed or a protective
    order is not obtained, the Confidential Information disclosed in response to
    such court or governmental order shall be limited to that information which
    is legally required to be disclosed in response to such court or
    governmental order;

          16.4.2 REQUIRED BY LAW. Otherwise required by law; provided, however,
    that the disclosing Party shall (a) provide the other Party with reasonable
    advance notice of and an opportunity to comment on any such required
    disclosure, (b) if requested by such other Party, seek confidential
    treatment with respect to any such disclosure to the extent available, and
    (c) use good faith efforts to incorporate the comments of such other Party
    in any such disclosure or request for confidential treatment;

          16.4.3 REQUIRED BY REGULATORY AUTHORITY. Made by such Party to the
    Regulatory Authorities as required in connection with any filing,
    application or request for Regulatory Approval; provided, however, that
    reasonable measures shall be taken to assure confidential treatment of such
    information; or

          16.4.4 REQUIRED BY AGREEMENT. Made by such Party, in connection with
    the performance of this Agreement, to Affiliates, Sublicensees, research
    parties, employees, consultants, representatives or agents, each of whom
    prior to disclosure must be bound by obligations of confidentiality and
    non-use at least equivalent in scope to those set forth in this Article 17.

     16.5 PRESS RELEASES. Press releases or other similar public communication
by either Party relating to this Agreement, shall be approved in advance by the
other Party, which approval shall not be unreasonably withheld or delayed,
except for those communications required by Applicable Law (which shall be
provided to the other Party as soon as practicable after the release or
communication thereof), disclosures of information for which consent has
previously been obtained, and information of a similar nature to that which has
been previously disclosed publicly with respect to this Agreement, each of which
shall not require advance approval.

                                       37
<PAGE>

                                   ARTICLE 17
                            MISCELLANEOUS PROVISIONS

     17.1 GOVERNING LAW. This Agreement shall be governed by and construed in
accordance with the laws of the State of New York, excluding any conflicts or
choice of law rule or principle that might otherwise refer construction or
interpretation of this Agreement to the substantive law of another jurisdiction.

     17.2 REGISTRATION. If this Agreement or any associated transaction is
required by the law of any nation to be either approved or registered with any
governmental agency, Licensee shall assume all legal obligations to do so and
the costs in connection therewith.

     17.3 TRADE REGULATIONS. Licensee shall observe all applicable United States
and foreign laws with respect to the transfer of Licensed Products and related
technical data to foreign countries, including the International Traffic in Arms
Regulations (ITAR) and the Export Administration Regulations.

     17.4 ENTIRE AGREEMENT. The Parties hereto acknowledge that this Agreement,
including the Appendices and documents incorporated by reference set forth the
entire agreement and understanding of the Parties hereto as to the subject
matter hereof, and shall not be subject to any change of modification except by
the execution of a written instrument subscribed to by the Parties hereto. This
Agreement shall supersede all previous communications, representations or
understandings, either oral or written, between the Parties relating to the
subject matter hereof.

     17.5 SEVERABILITY. If any provision of this Agreement is held to be
illegal, invalid or unenforceable under any present or future law, and if the
rights or obligations of either Party under this Agreement will not be
materially and adversely affected thereby, (a) such provision shall be fully
severable, (b) this Agreement shall be construed and enforced as if such
illegal, invalid or unenforceable provision had never comprised a part hereof,
(c) the remaining provisions of this Agreement shall remain in full force and
effect and shall not be affected by the illegal, invalid or unenforceable
provision or by its severance herefrom, and (d) in lieu of such illegal, invalid
or unenforceable provision, there shall be added automatically as a part of this
Agreement a legal, valid and enforceable provision as similar in terms to such
illegal, invalid or unenforceable provision as may be possible and reasonably
acceptable to the Parties herein. To the fullest extent permitted by applicable
law, each Party hereby waives any provision of law that would render any
provision prohibited or unenforceable in any respect.

     17.6 WAIVER. The failure of either Party to assert a right hereunder or to
insist upon compliance with any term or condition of this Agreement shall not
constitute a waiver of that right or excuse a similar subsequent failure to
perform any such term or condition by the other Party.

     17.7 FORCE MAJEURE. Neither Party shall be held liable or responsible to
the other Party or be deemed to have defaulted under or breached this Agreement
for failure or delay in fulfilling or performing any term of this Agreement when
such failure or delay is caused by or results from causes beyond the reasonable
control of the non-performing Party, including fires, floods, earthquakes,
embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be
declared or not), acts of terrorism, insurrections, riots, civil commotion,
strikes, lockouts or other labor disturbances, acts of God or acts, omissions or

                                       38
<PAGE>

delays in acting by any governmental authority. The non-performing Party shall
notify the other Party of such force majeure within ten (10) days after such
occurrence by giving written notice to the other Party stating the nature of the
event, its anticipated duration, and any action being taken to avoid or minimize
its effect. The suspension of performance shall be of no greater scope and no
longer duration than is necessary and the non-performing Party shall use
commercially reasonable efforts to remedy its inability to perform; provided,
however, that in the event the suspension of performance continues for
one-hundred and eighty (180) days after the date of the occurrence, and such
failure to perform would constitute a material breach of this Agreement in the
absence of such force majeure, the non-performing Party may terminate this
Agreement pursuant by written notice to the other Party.

     17.8 CONSTRUCTION. Except where the context otherwise requires, wherever
used, the singular shall include the plural, the plural the singular, the use of
any gender shall be applicable to all genders and the word "or" is used in the
inclusive sense (and/or). The captions of this Agreement are for convenience of
reference only and in no way define, describe, extend or limit the scope or
intent of this Agreement or the intent of any provision contained in this
Agreement. The term "including" as used herein shall mean including, without
limiting the generality of any description preceding such term. The language of
this Agreement shall be deemed to be the language mutually chosen by the Parties
and no rule of strict construction shall be applied against either Party hereto.

     17.9 FURTHER ASSURANCE. Each Party shall duly execute and deliver, or cause
to be duly executed and delivered, such further instruments and do and cause to
be done such further acts and things, including the filing of such assignments,
agreements, documents and instruments, as may be necessary or as the other Party
may reasonably request in connection with this Agreement or to carry out more
effectively the provisions and purposes, or to better assure and confirm unto
such other Party its rights and remedies under this Agreement.

     17.10 COUNTERPARTS. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

     17.11 BINDING. This Agreement shall not be binding upon the Parties until
it has been signed below on behalf of each Party, in which event, it shall be
effective as of the Effective Date.

                                       39
<PAGE>

      IN WITNESS WHEREOF, the duly authorized officers of the Parties have
executed this Agreement as of the dates set forth below their respective
signatures.

NOVADEL PHARMACEUTICAL              THE VETERINARY COMPANY
CORPORATION

By: /s/ Gary Shangold, MD                 By: /s/ Dennis Steadman
    --------------------------                --------------------------
Name:  Gary Shangold, M.D.                    Name:  Dennis Steadman
Title: President and CEO                      Title: CEO and President
Date:  June 22, 2004                          Date:  June 22, 2004

                                       40

<PAGE>

                                    EXHIBIT 1
                                    ---------

                             MANUFACTURING AGREEMENT

                    FORMULATION DEVELOPMENT TIMING FOR PROOF
                                OF CONCEPT STAGE

                                      [***]
--------------------------------------------------------------------------------

INFORMATION MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. THE OMITTED PORTION HAS BEEN SEPARATELY FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION.

                                       41
<PAGE>

                                    EXHIBIT 2
                                    ---------

                               NovaDel Pharma Inc.
                               -------------------
                             Project Employee Costs
                             ----------------------

                                      [***]
                                      -----

Information marked by [***] has been omitted pursuant to a request for
confidential treatment. The omitted portion has been separately filed with the
Securities and Exchange Commission.

                                       42
<PAGE>

                                    EXHIBIT 3
                              DESIGNATED COMPOUNDS
                              --------------------

                                       43

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}]]